<?xml version="1.0" encoding="UTF-8"?>
<svg height="777.49" width="545.206" xmlns="http://www.w3.org/2000/svg">
 <g id="page" xmlns:svgx="http://www.xml-cml.org/schema/svgx">
  <path style="fill:none;stroke:rgb(0,0,0);stroke-width:1.0;" d="M49.610 53.720 L532.910 53.720 "/>
  <g begin="text">
   <text y="49.34" x="49.606,54.606,59.606,64.606" svgx:width="0.5,0.5,0.5,0.28" style="fill:rgb(0,0,0);font-family:GillSansStd;font-size:10.0px;stroke:none;">452 </text>
   <text y="49.34" x="438.646,443.126,447.606,451.146,453.956,458.336,461.466,464.246,468.826,473.206,476.746,480.286,482.166,486.646,491.336,494.116,499.326,501.306,504.086,509.296,514.506,517.286,520.206,524.786,529.996" svgx:width="0.45,0.45,0.35,0.28,0.44,0.31,0.28,0.46,0.44,0.35,0.35,0.19,0.45,0.47,0.28,0.52,0.2,0.28,0.52,0.52,0.28,0.29,0.46,0.52,0.29" style="fill:rgb(0,0,0);font-family:GillSansStd-Italic;font-size:10.0px;stroke:none;">Poster session 2, 20 (s1)</text>
  </g>
  <g begin="text">
   <text y="767.49" x="49.606,57.736,62.426,64.306,67.116,68.996,73.896,75.776,80.156,82.936,87.516,91.366,93.246,97.626,100.756,105.236,108.776,110.656,114.196,116.976,119.376,123.856,128.546,131.676,136.366,141.056" svgx:width="0.81,0.47,0.19,0.28,0.19,0.49,0.19,0.44,0.28,0.46,0.38,0.19,0.44,0.31,0.45,0.35,0.19,0.35,0.28,0.24,0.45,0.47,0.31,0.47,0.47,0.19" style="fill:rgb(0,0,0);font-family:GillSansStd-Italic;font-size:10.0px;stroke:none;">Multiple Sclerosis Journal</text>
   <text y="767.49" x="142.936,145.716,150.716,155.716,160.716,165.716,167.906,170.686,175.686,180.686,182.876,185.656,188.886,193.466,198.466,201.696,204.476,209.476,214.476,219.476,224.476,229.476,234.476" svgx:width="0.28,0.5,0.5,0.5,0.5,0.22,0.28,0.5,0.5,0.22,0.28,0.32,0.46,0.5,0.32,0.28,0.5,0.5,0.5,0.5,0.5,0.5,0.5" style="fill:rgb(0,0,0);font-family:GillSansStd;font-size:10.0px;stroke:none;"> 2014; 20: (S1) 285â€“496</text>
  </g>
  <g begin="text">
   <text y="767.42" x="466.181,473.891,477.741,479.931,482.121,485.971,490.241,494.511,499.301,504.301,509.301,514.201,516.391,520.771,526.291" svgx:width="0.77,0.38,0.22,0.22,0.38,0.43,0.43,0.48,0.5,0.5,0.5,0.22,0.44,0.55,0.77" style="fill:rgb(0,0,0);font-family:GillSansStd;font-size:10.0px;stroke:none;">msj.sagepub.com</text>
  </g>
  <path style="fill:none;stroke:rgb(0,0,0);stroke-width:0.25;" d="M49.610 122.160 L85.350 122.160 "/>
  <path style="fill:none;stroke:rgb(0,0,0);stroke-width:0.44;" d="M49.610 726.160 L80.850 726.160 "/>
  <g begin="text">
   <text y="76.959" x="49.606,55.105,59.605,64.105" svgx:width="0.61,0.5,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">P879</text>
   <text y="87.957" x="49.606,56.104,58.606,62.107,66.607,71.611,74.113,76.615,79.117,82.114,86.614,88.864,93.868,97.864,102.364,106.864,110.86,114.856,118.357,121.858,124.36,128.86,133.864,136.114,140.614,144.115,147.616,152.116,156.112,158.614,163.114,166.111,170.107,175.111,177.361,183.859,186.361,189.358,194.362,196.612,199.609,203.605,208.105,213.109,216.61,219.112,222.109,224.611,229.111,234.115,236.617,241.621,246.121" svgx:width="0.72,0.28,0.39,0.5,0.56,0.28,0.28,0.28,0.33,0.5,0.25,0.56,0.44,0.5,0.5,0.44,0.44,0.39,0.39,0.28,0.5,0.56,0.25,0.5,0.39,0.39,0.5,0.44,0.28,0.5,0.33,0.44,0.56,0.25,0.72,0.28,0.33,0.56,0.25,0.33,0.44,0.5,0.56,0.39,0.28,0.33,0.28,0.5,0.56,0.28,0.56,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Disability progression associated with transitioning </text>
   <text y="98.955" x="49.606,52.603,56.599,60.595,65.095,68.092,75.589,79.585,84.589,87.586,89.836,94.336,97.333,100.33,104.326,108.322,110.572,115.072,118.069,122.569,126.565,131.065,135.061,138.562,140.812,145.312,148.309,150.559,155.563,160.063,163.06,167.56,170.062,172.564,176.56,181.564,189.061,193.561,198.565,200.815,203.812,208.816,212.812,216.808,221.308,226.312,230.812,233.062,237.562,241.063" svgx:width="0.33,0.44,0.44,0.5,0.33,0.83,0.44,0.56,0.33,0.25,0.5,0.33,0.33,0.44,0.44,0.25,0.5,0.33,0.5,0.44,0.5,0.44,0.39,0.25,0.5,0.33,0.25,0.56,0.5,0.33,0.5,0.28,0.28,0.44,0.56,0.83,0.5,0.56,0.25,0.33,0.56,0.44,0.44,0.5,0.56,0.5,0.25,0.5,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">treatment after 2-years of natalizumab therapy as </text>
   <text y="109.953" x="49.606,53.602,57.598,62.602,67.102,71.098,74.095,78.091,83.095,85.345,90.349,94.849,97.099,103.597,110.095,116.593,123.091,130.093,138.589,143.593,145.843,150.847,155.347,159.343,162.34,164.842,168.838,171.34,176.344,180.844,185.848,188.845" svgx:width="0.44,0.44,0.56,0.5,0.44,0.33,0.44,0.56,0.25,0.56,0.5,0.25,0.72,0.72,0.72,0.72,0.78,0.94,0.56,0.25,0.56,0.5,0.44,0.33,0.28,0.44,0.28,0.56,0.5,0.56,0.33,0.39" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">reported by NARCOMS participants</text>
   <text y="120.951" x="49.606,56.104,62.107,64.357,69.361,73.357,75.859,78.361,82.357" svgx:width="0.72,0.67,0.25,0.56,0.44,0.28,0.28,0.44,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">AR Salter</text>
   <text y="118.439" x="85.354" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="120.959" x="88.279,90.529,92.779,97.783,102.787,105.037,111.04,115.54,118.537,121.039,125.035,127.537" svgx:width="0.25,0.25,0.56,0.56,0.25,0.67,0.5,0.33,0.28,0.44,0.28,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, SS Cofield</text>
   <text y="118.439" x="132.036" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="120.959" x="134.961,137.211,139.461,145.464,148.965,151.215,156.219,160.719" svgx:width="0.25,0.25,0.67,0.39,0.25,0.56,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, RJ Fox</text>
   <text y="118.439" x="165.219" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">2</text>
   <text y="120.959" x="168.144,170.394,172.644,178.143,180.393,185.892,190.392,193.389" svgx:width="0.25,0.25,0.61,0.25,0.61,0.5,0.33,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, T Tyry</text>
   <text y="118.439" x="197.889" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">3</text>
   <text y="120.959" x="200.814,203.064,205.314,211.812,214.062,220.065,224.061,231.063,235.563,239.559,244.059,248.559,253.059,255.561" svgx:width="0.25,0.25,0.72,0.25,0.67,0.44,0.78,0.5,0.44,0.5,0.5,0.5,0.28,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, D Campagnolo</text>
   <text y="118.439" x="260.061" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">4</text>
   <text y="120.959" x="262.986,265.236" svgx:width="0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, </text>
   <text y="131.957" x="49.605,57.606,61.107,63.357,68.361,72.357,76.857,80.853,83.355,85.857" svgx:width="0.89,0.39,0.25,0.56,0.44,0.5,0.44,0.28,0.28,0.28" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">MJ Fanelli</text>
   <text y="129.439" x="88.36" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">4</text>
   <text y="131.959" x="91.285,93.535,95.785,101.284,103.534,109.033,111.535,116.035,118.537,123.037,127.537,131.038,133.54,138.04" svgx:width="0.25,0.25,0.61,0.25,0.61,0.28,0.5,0.28,0.5,0.5,0.39,0.28,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, T Livingston</text>
   <text y="129.439" x="142.54" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">4</text>
   <text y="140.437" x="49.606" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">1</text>
   <text y="142.959" x="52.531,59.029,63.529,66.031,70.027,74.023,77.524,81.025,83.527,86.029,90.025,92.275,96.775,99.277,101.527,107.026,109.528,114.028,118.528,123.028,129.526,134.026,136.276,140.776,143.278,145.528,151.027,153.529,157.03,163.528,166.03,170.53,175.03,179.53,184.03,190.528,192.778,195.028,200.527,203.029,206.53,213.028,215.53,220.03,224.53,229.03,233.53,240.028,242.278,244.528,250.027,255.031,257.281,259.531,266.029,270.529,273.031,275.533,279.529,284.029" svgx:width="0.72,0.5,0.28,0.44,0.44,0.39,0.39,0.28,0.28,0.44,0.25,0.5,0.28,0.25,0.61,0.28,0.5,0.5,0.5,0.72,0.5,0.25,0.5,0.28,0.25,0.61,0.28,0.39,0.72,0.28,0.5,0.5,0.5,0.5,0.72,0.25,0.25,0.61,0.28,0.39,0.72,0.28,0.5,0.5,0.5,0.5,0.72,0.25,0.25,0.61,0.56,0.25,0.25,0.72,0.5,0.28,0.28,0.44,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">University of Alabama at Birmingham, Birmingham, AL, United </text>
   <text y="153.957" x="49.606,54.106,56.608,61.108,63.61,67.606,71.107,73.357" svgx:width="0.5,0.28,0.5,0.28,0.44,0.39,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">States, </text>
   <text y="151.439" x="75.607" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">2</text>
   <text y="153.959" x="78.532,86.029,90.025,92.527,95.029,99.025,103.525,105.775,111.778,115.774,120.274,122.776,126.772,130.273,132.523,135.025,139.525,143.026,145.276,152.773,157.273,159.775,162.277,164.779,169.279,171.781,175.777,178.027,182.527,186.523,189.025,193.021,196.522,201.022,204.523,207.025,210.526,212.776,215.026,220.03,224.026,227.527,232.027,236.023,239.524,241.774,247.777,252.277,254.779,257.281,261.277,265.777,269.773,272.023,276.523,279.025" svgx:width="0.83,0.44,0.28,0.28,0.44,0.5,0.25,0.67,0.44,0.5,0.28,0.44,0.39,0.25,0.28,0.5,0.39,0.25,0.83,0.5,0.28,0.28,0.28,0.5,0.28,0.44,0.25,0.5,0.44,0.28,0.44,0.39,0.5,0.39,0.28,0.39,0.25,0.25,0.56,0.44,0.39,0.5,0.44,0.39,0.25,0.67,0.5,0.28,0.28,0.44,0.5,0.44,0.25,0.5,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Mellen Center for Multiple Sclerosis, Lerner College of </text>
   <text y="164.957" x="49.606,57.103,61.099,65.599,68.101,72.097,74.599,79.099,83.095,85.345,87.595,93.598,96.1,100.096,104.092,108.088,110.59,115.09,119.59,124.09,126.34,128.59,135.088,141.586,143.836,146.086,152.584,157.084,159.586,162.088,166.084,170.584,172.834,177.334,179.836,184.336,186.838,190.834,194.335,196.585" svgx:width="0.83,0.44,0.5,0.28,0.44,0.28,0.5,0.44,0.25,0.25,0.67,0.28,0.44,0.44,0.44,0.28,0.5,0.5,0.5,0.25,0.25,0.72,0.72,0.25,0.25,0.72,0.5,0.28,0.28,0.44,0.5,0.25,0.5,0.28,0.5,0.28,0.44,0.39,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Medicine, Cleveland, OH, United States, </text>
   <text y="162.439" x="198.833" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">3</text>
   <text y="164.959" x="201.758,206.258,208.76,211.01,213.26,217.257,221.757,225.258,229.254,233.754,238.254,241.251,244.752,247.002,253.5,258.0,261.501,266.001,268.503,271.005,275.505,278.007" svgx:width="0.5,0.28,0.25,0.25,0.44,0.5,0.39,0.44,0.5,0.5,0.33,0.39,0.25,0.72,0.5,0.39,0.5,0.28,0.28,0.5,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">St. Josephâ€™s Hospital </text>
   <text y="175.957" x="49.604,54.104,58.604,63.104,65.354,72.851,76.847,81.347,83.849,87.845,92.345,94.847,97.097,103.1,107.096,111.596,114.098,118.094,121.595,123.845,126.095,131.594,136.094,140.594,144.59,149.09,151.592,155.589,157.839,160.089,165.587,170.591,172.841,175.091,181.589,186.089,188.591,191.093,195.089,199.589,201.839,206.339,208.841,213.341,215.843,219.839,223.34,225.59" svgx:width="0.5,0.5,0.5,0.25,0.83,0.44,0.5,0.28,0.44,0.5,0.28,0.25,0.67,0.44,0.5,0.28,0.44,0.39,0.25,0.25,0.61,0.5,0.5,0.44,0.5,0.28,0.44,0.25,0.25,0.61,0.56,0.25,0.25,0.72,0.5,0.28,0.28,0.44,0.5,0.25,0.5,0.28,0.5,0.28,0.44,0.39,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">and Medical Center, Phoenix, AZ, United States, </text>
   <text y="173.439" x="227.841" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">4</text>
   <text y="175.959" x="230.766,236.265,238.767,243.267,247.767,251.763,256.263,258.513,261.51,266.01,270.006,274.002,276.252" svgx:width="0.61,0.28,0.5,0.5,0.44,0.5,0.25,0.33,0.5,0.44,0.44,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Biogen Idec, </text>
   <text y="186.957" x="49.605,55.608,60.108,66.606,71.106,74.607,77.109,81.609,86.109,90.105,92.355,94.605,102.102,107.601,109.851,112.101,118.599,123.099,125.601,128.103,132.099,136.599,138.849,143.349,145.851,150.351,152.853,156.849" svgx:width="0.67,0.5,0.72,0.5,0.39,0.28,0.5,0.5,0.44,0.25,0.25,0.83,0.61,0.25,0.25,0.72,0.5,0.28,0.28,0.44,0.5,0.25,0.5,0.28,0.5,0.28,0.44,0.39" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Cambridge, MA, United States</text>
   <text y="213.957" x="49.605,55.608,60.108,64.104,69.108,73.608,77.442,81.942,86.946,91.95,96.954,99.951" svgx:width="0.67,0.5,0.44,0.56,0.5,0.44,0.5,0.56,0.56,0.56,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Background: </text>
   <text y="213.957" x="102.219,107.718,112.218,116.214,118.482,122.478,126.978,131.478,134.979,138.975,143.475,147.975,151.971,156.471,160.467,164.463,167.964,170.223,174.723,177.72,179.988,182.49,185.487,189.483,193.983,197.484,199.986,202.488,204.99,209.49,213.99,216.492,220.992,225.492,227.751,230.253,234.753,237.021,241.017,245.517,250.017,252.519,257.019,261.015,264.012,266.271,268.773,271.77,275.766,279.762,282.264" svgx:width="0.61,0.5,0.44,0.25,0.44,0.5,0.5,0.39,0.44,0.5,0.5,0.44,0.5,0.44,0.44,0.39,0.25,0.5,0.33,0.25,0.28,0.33,0.44,0.5,0.39,0.28,0.28,0.28,0.5,0.5,0.28,0.5,0.5,0.25,0.28,0.5,0.25,0.44,0.5,0.5,0.28,0.5,0.44,0.33,0.25,0.28,0.33,0.44,0.44,0.28,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">The consequences of transitioning to another treat-</text>
   <text y="224.955" x="49.605,56.607,60.603,65.103,67.605,69.855,71.628,75.624,78.621,81.123,85.119,88.116,90.366,92.139,96.639,98.889,100.662,105.162,109.158,113.154,116.151,119.652,121.902,123.675,128.175,131.172,133.422,135.195,139.695,143.691,146.193,150.189,152.691,155.193,159.189,163.689,170.691,174.687,179.187,181.437,183.21,186.207,192.705,198.204,203.703,206.7,208.95,210.723,215.223,219.219,223.719,227.715,229.965,231.738,236.238,240.738,243.24,245.49,247.263,251.763,255.759,259.755,264.255,266.505,268.278,271.275,275.775,278.277,280.779,285.279" svgx:width="0.78,0.44,0.5,0.28,0.25,0.55,0.44,0.33,0.28,0.44,0.33,0.25,0.55,0.5,0.25,0.55,0.5,0.44,0.44,0.33,0.39,0.25,0.55,0.5,0.33,0.25,0.55,0.5,0.44,0.28,0.44,0.28,0.28,0.44,0.5,0.78,0.44,0.5,0.25,0.55,0.33,0.72,0.72,0.61,0.33,0.25,0.55,0.5,0.44,0.5,0.44,0.25,0.55,0.5,0.5,0.28,0.25,0.55,0.5,0.44,0.44,0.5,0.25,0.55,0.33,0.5,0.28,0.28,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">ment after 2 years of natalizumab (NAT) have not been fully </text>
   <text y="235.953" x="49.605,54.105,58.101,60.603,64.599,67.596,74.598,77.1,81.6,85.596,90.096" svgx:width="0.5,0.44,0.28,0.44,0.33,0.78,0.28,0.5,0.44,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">determined.</text>
   <text y="246.951" x="49.605,56.562,61.521,64.473,68.424,72.375,75.327,77.784,82.239,86.19,89.646,92.598" svgx:width="0.78,0.56,0.33,0.44,0.44,0.33,0.28,0.5,0.44,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Objectives: </text>
   <text y="246.951" x="95.208,100.032,104.487,107.097,110.049,114.0,116.457,119.409,123.864,127.32,131.775,135.726,139.677,142.134,144.591,149.046,152.997,155.454,159.909,162.519,166.47,170.925,177.882,182.337,186.288,189.24,193.191,195.801,200.256,202.713,206.169,210.12,214.575,217.032,219.489,221.946,224.403,228.858,231.468,235.923,238.875,243.33,247.785,250.737,254.688,258.144,261.6,264.057,268.512,272.967,275.172,277.782,281.733,285.234" svgx:width="0.61,0.5,0.25,0.33,0.44,0.28,0.33,0.5,0.39,0.5,0.44,0.44,0.28,0.28,0.5,0.44,0.28,0.5,0.25,0.44,0.5,0.78,0.5,0.44,0.33,0.44,0.25,0.5,0.28,0.39,0.44,0.5,0.28,0.28,0.28,0.28,0.5,0.25,0.5,0.33,0.5,0.5,0.33,0.44,0.39,0.39,0.28,0.5,0.5,0.25,0.25,0.44,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">To retrospectively compare disability progression, as </text>
   <text y="257.949" x="49.605,56.562,60.513,64.464,67.92,72.375,75.327,79.278,83.733,85.983,89.853,94.308,98.763,101.013,104.883,107.34,111.795,115.746,118.698,122.649,126.6,130.056,134.007,136.257,140.127,142.584,147.039,149.289,153.159,158.118,162.069,164.526,166.983,170.934,175.389,177.846,180.096,183.966,190.419,194.37,196.827,200.778,203.73,210.687,213.144,217.599,221.55,226.005,228.255,232.125,238.578,241.035,244.491,248.442,252.393,255.849,259.8,262.05,265.92,270.879,273.336,277.287,281.742,285.243" svgx:width="0.78,0.44,0.44,0.39,0.5,0.33,0.44,0.5,0.25,0.55,0.5,0.5,0.25,0.55,0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.25,0.55,0.28,0.5,0.25,0.55,0.56,0.44,0.28,0.28,0.44,0.5,0.28,0.25,0.55,0.72,0.44,0.28,0.44,0.33,0.78,0.28,0.5,0.44,0.5,0.25,0.55,0.72,0.28,0.39,0.44,0.44,0.39,0.44,0.25,0.55,0.56,0.28,0.44,0.5,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">measured by increase in Patient Determined Disease Steps </text>
   <text y="268.947" x="49.605,52.557,57.516,63.969,70.422,75.381,78.333,80.538,82.788,84.3,86.757,91.212,93.462,94.974,101.427,107.88,113.838,119.796,126.249,134.205,139.164,141.414,142.926,147.381,151.332,154.284,156.741,159.198,163.149,165.606,170.061,174.012,178.467,180.924,184.38,186.63,188.142,194.595,199.05,203.505,205.755,207.267,210.219,214.17,221.127,225.078,227.535,231.99,235.941,240.396,242.646,244.158,248.613,253.068,255.318,256.83,263.283,268.737,274.029,276.279,277.791,282.246,285.243" svgx:width="0.33,0.56,0.72,0.72,0.56,0.33,0.25,0.25,0.55,0.28,0.5,0.25,0.55,0.72,0.72,0.67,0.67,0.72,0.89,0.56,0.25,0.55,0.5,0.44,0.33,0.28,0.28,0.44,0.28,0.5,0.44,0.5,0.28,0.39,0.25,0.55,0.72,0.5,0.5,0.25,0.55,0.33,0.44,0.78,0.44,0.28,0.5,0.44,0.5,0.25,0.55,0.5,0.5,0.25,0.55,0.72,0.72,0.61,0.25,0.55,0.5,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">(PDDS), in NARCOMS participants who remained on NAT or </text>
   <text y="279.945" x="49.605,52.062,55.014,58.965,63.42,66.876,69.333,71.79,74.247,78.702,83.157,87.108,91.563,93.795,96.252,100.707,102.939,105.891,108.348,112.803,117.258,121.713,124.17,126.627,133.584,138.039,142.494,144.726,147.678,152.637,155.589,162.042,164.994,167.226,171.681,174.633,176.865,179.322,183.777,186.234,190.185,194.136,196.593,200.544,204.999,207.456,211.407,213.639,216.096,220.551,224.502,227.454,231.405,235.86,238.317,242.268,245.724,247.956,250.908,253.86,260.313,263.769,266.721,268.953,272.904,275.856,278.313,282.264,285.261" svgx:width="0.28,0.33,0.44,0.5,0.39,0.28,0.28,0.28,0.5,0.5,0.44,0.5,0.25,0.28,0.5,0.25,0.33,0.28,0.5,0.5,0.5,0.28,0.28,0.78,0.5,0.5,0.25,0.33,0.56,0.33,0.72,0.33,0.25,0.5,0.33,0.25,0.28,0.5,0.28,0.44,0.44,0.28,0.44,0.5,0.28,0.44,0.25,0.28,0.5,0.44,0.33,0.44,0.5,0.28,0.44,0.39,0.25,0.33,0.33,0.72,0.39,0.33,0.25,0.44,0.33,0.28,0.44,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">transitioned to fingolimod (FIN) or injectable therapies (INJ) after </text>
   <text y="290.943" x="49.605,54.06,56.265,60.72,64.671,68.622,71.574,75.03,77.235,81.69,84.642,86.847,93.3,98.754,103.542" svgx:width="0.5,0.25,0.5,0.44,0.44,0.33,0.39,0.25,0.5,0.33,0.25,0.72,0.72,0.61,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">2 years of NAT.</text>
   <text y="301.941" x="49.605,58.056,62.007,64.959,69.918,74.373,79.332,82.788,85.74" svgx:width="0.94,0.44,0.33,0.56,0.5,0.56,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Methods: </text>
   <text y="301.941" x="89.781,96.234,102.687,108.645,114.603,121.056,129.012,133.971,136.221,138.012,142.467,146.418,149.37,151.827,154.284,158.235,160.692,165.147,169.098,173.553,176.01,179.466,181.716,183.507,189.96,192.417,194.874,199.329,201.579,203.37,208.329,214.782,221.235,226.194,228.444,230.235,233.187,237.138,241.593,246.048,249.0,251.457,255.408,259.863,262.113,263.904,267.855,270.312,272.562,274.353,276.81,281.265,285.261" svgx:width="0.72,0.72,0.67,0.67,0.72,0.89,0.56,0.25,0.55,0.5,0.44,0.33,0.28,0.28,0.44,0.28,0.5,0.44,0.5,0.28,0.39,0.25,0.55,0.72,0.28,0.28,0.5,0.25,0.55,0.56,0.72,0.72,0.56,0.25,0.55,0.33,0.44,0.5,0.5,0.33,0.28,0.44,0.5,0.25,0.55,0.44,0.28,0.25,0.55,0.28,0.5,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">NARCOMS participants with PDDS reported at the </text>
   <text y="312.939" x="49.605,53.061,55.518,59.469,62.421,64.878,66.48,70.935,73.887,75.489,79.44,83.895,88.35,89.952,94.848,99.303,100.905,107.862,112.317,116.772,119.229,123.684,127.14,128.742,132.693,135.645,138.102,142.053,145.005,146.607,151.062,152.664,157.119,161.07,165.021,167.973,171.429,173.031,177.486,180.438,182.04,188.493,193.947,199.239,200.841,207.294,211.245,214.197,218.148,219.75,222.207,226.662,230.613,233.07,237.525,241.98,245.931,250.386,251.988,254.94,261.393,266.424,270.879,275.334,279.789,282.741,285.243" svgx:width="0.39,0.28,0.44,0.33,0.28,0.25,0.5,0.33,0.25,0.44,0.5,0.5,0.25,0.55,0.5,0.25,0.78,0.5,0.5,0.28,0.5,0.39,0.25,0.44,0.33,0.28,0.44,0.33,0.25,0.5,0.25,0.5,0.44,0.44,0.33,0.39,0.25,0.5,0.33,0.25,0.72,0.72,0.61,0.25,0.72,0.44,0.33,0.44,0.25,0.28,0.5,0.44,0.28,0.5,0.5,0.44,0.5,0.25,0.33,0.72,0.56,0.5,0.5,0.5,0.33,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">start of and â‰¥6 months after 2 years of NAT were included (N=527); </text>
   <text y="323.937" x="49.605,54.06,57.012,61.467,65.922,70.377,73.833,76.164,82.617,86.568,89.52,93.471,95.802,100.257,104.208,107.664,111.615,116.07,118.392,122.847,127.302,129.633,132.09,135.042,138.993,142.944,145.401,152.358,156.309,160.764,163.221,166.677,168.999,173.454,176.91,180.861,185.316,187.647,191.598,194.55,197.007,200.958,203.91,206.241,210.696,213.018,217.473,221.424,225.375,228.327,231.783,234.114,238.569,241.521,243.843,250.296,255.75,261.042,263.373,266.325,272.778,278.232,283.02,285.27" svgx:width="0.5,0.33,0.5,0.5,0.5,0.39,0.25,0.72,0.44,0.33,0.44,0.25,0.5,0.44,0.39,0.44,0.5,0.25,0.5,0.5,0.25,0.28,0.33,0.44,0.44,0.28,0.78,0.44,0.5,0.28,0.39,0.25,0.5,0.39,0.44,0.5,0.25,0.44,0.33,0.28,0.44,0.33,0.25,0.5,0.25,0.5,0.44,0.44,0.33,0.39,0.25,0.5,0.33,0.25,0.72,0.72,0.61,0.25,0.33,0.72,0.72,0.61,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">groups were based on treatments used after 2 years of NAT (NAT, </text>
   <text y="334.935" x="49.605,56.058,61.089,65.544,69.999,74.454,76.911,79.539,84.498,87.45,93.903,96.108,98.736,105.189,110.22,114.675,119.13,121.587,124.215,127.167,133.62,137.076,139.281,141.909,148.362,153.393,157.848,162.303,165.255,167.46,170.088,175.047,177.999,182.454,186.909,190.86,195.315,198.771,201.228,203.685,208.14,210.768,214.224,218.175,222.63,225.582,229.533,232.989,235.617,238.569,243.024,246.975,249.927,252.384,256.839,260.79,265.245,267.873,270.825,273.777,278.232,285.234" svgx:width="0.72,0.56,0.5,0.5,0.5,0.28,0.25,0.56,0.33,0.72,0.25,0.25,0.72,0.56,0.5,0.5,0.28,0.25,0.33,0.72,0.39,0.25,0.25,0.72,0.56,0.5,0.5,0.33,0.25,0.25,0.56,0.33,0.5,0.5,0.44,0.5,0.39,0.28,0.28,0.5,0.25,0.39,0.44,0.5,0.33,0.44,0.39,0.25,0.33,0.5,0.44,0.33,0.28,0.5,0.44,0.5,0.25,0.33,0.33,0.5,0.78,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">N=406; FIN, N=50; INJ, N=71). Propensity scores (derived from </text>
   <text y="345.933" x="49.605,53.556,58.011,61.962,64.167,66.921,70.377,74.328,78.783,80.988,83.742,88.701,95.154,101.607,106.566,108.771,111.525,115.476,119.931,124.386,127.14,131.595,134.547,137.004,141.459,144.411,147.165,150.117,154.068,156.525,160.476,164.931,168.387,172.338,175.092,179.043,182.994,185.451,187.908,192.363,194.82,197.277,201.732,204.684,207.438,213.891,217.842,220.794,224.745,227.499,231.954,235.41,239.361,243.816,246.57,249.027,253.482,256.236,259.188,263.643,266.595,273.552,276.306,280.761,285.261" svgx:width="0.44,0.5,0.44,0.25,0.25,0.39,0.44,0.5,0.25,0.25,0.56,0.72,0.72,0.56,0.25,0.25,0.44,0.5,0.5,0.25,0.5,0.33,0.28,0.5,0.33,0.25,0.33,0.44,0.28,0.44,0.5,0.39,0.44,0.25,0.44,0.44,0.28,0.28,0.5,0.28,0.28,0.5,0.33,0.25,0.72,0.44,0.33,0.44,0.25,0.5,0.39,0.44,0.5,0.25,0.28,0.5,0.25,0.33,0.5,0.33,0.78,0.25,0.5,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">age, sex, PDDS, and prior relapse activity) were used to form 50 </text>
   <text y="356.931" x="49.605,53.556,58.011,62.466,64.71600000000001,65.391,69.846,74.301,77.226,81.681,85.632,88.584,91.041,93.498,97.449,99.906,104.361,108.312,112.767,115.224,118.149,122.604,126.555,129.012,131.964,135.42,137.67,138.345,142.8,146.751,149.208,155.661,159.612,163.563,168.018,170.268,170.943,177.396,182.85,187.476,190.428,195.387,198.339,204.792,207.042,207.717,211.668,216.123,220.578,223.503,229.956,235.41,240.036,242.988,245.94,252.393,255.849,258.099,258.774,263.229,266.181,270.636,275.091,279.546,283.002,285.252" svgx:width="0.44,0.5,0.5,0.25,0.55,0.5,0.5,0.25,0.5,0.44,0.33,0.28,0.28,0.44,0.28,0.5,0.44,0.5,0.28,0.25,0.5,0.44,0.28,0.33,0.39,0.25,0.55,0.5,0.44,0.28,0.72,0.44,0.44,0.5,0.25,0.55,0.72,0.72,0.61,0.33,0.56,0.33,0.72,0.25,0.55,0.44,0.5,0.5,0.25,0.72,0.72,0.61,0.33,0.33,0.72,0.39,0.25,0.55,0.5,0.33,0.5,0.5,0.5,0.39,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">and 45 participant pairs between NAT-FIN and NAT-INJ groups, </text>
   <text y="367.929" x="49.605,52.557,56.508,59.964,64.419,68.37,72.321,74.778,77.235,81.69,85.641,88.098,91.968,94.173,96.693,101.652,106.107,109.059,111.579,116.034,119.985,122.442,125.394,129.345,133.8,136.32,140.271,144.726,149.181,151.701,156.156,160.611,165.066,169.017,171.474,174.426,178.377,182.832,185.352,189.807,193.758,196.215,200.166,203.622,207.573,210.03,213.486,215.691,218.211,222.666,226.617,229.569,232.026,234.483,238.434,240.891,245.346,249.297,253.752,256.209,258.729,263.184,266.136,270.591,275.046,279.501,282.264" svgx:width="0.33,0.44,0.39,0.5,0.44,0.44,0.28,0.28,0.5,0.44,0.28,0.5,0.25,0.25,0.56,0.5,0.33,0.25,0.5,0.44,0.28,0.33,0.44,0.5,0.25,0.44,0.5,0.5,0.25,0.5,0.5,0.5,0.44,0.28,0.33,0.44,0.5,0.25,0.5,0.44,0.28,0.44,0.39,0.44,0.28,0.39,0.25,0.25,0.5,0.44,0.33,0.28,0.28,0.44,0.28,0.5,0.44,0.5,0.28,0.25,0.5,0.33,0.5,0.5,0.5,0.33,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">respectively. For paired and unpaired datasets, participant propor-</text>
   <text y="378.927" x="49.605,52.062,54.519,58.974,63.429,66.885,69.135,70.305,76.758,79.215,81.672,86.127,88.377,89.547,94.506,100.959,107.412,112.371,114.621,115.791,118.248,122.703,126.654,129.606,133.557,137.508,140.964,144.915,147.165,148.335,152.286,156.741,161.196,163.446,164.616,171.573,175.524,179.475,183.93,186.18,187.35,192.309,198.762,205.215,210.174,212.424,213.594,216.051,220.506,224.457,227.409,231.36,235.311,238.767,242.718,244.968,246.138,252.591,256.542,259.494,263.445,265.695,266.865,270.816,275.271,282.228" svgx:width="0.28,0.28,0.5,0.5,0.39,0.25,0.55,0.72,0.28,0.28,0.5,0.25,0.55,0.56,0.72,0.72,0.56,0.25,0.55,0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.78,0.44,0.44,0.5,0.25,0.55,0.56,0.72,0.72,0.56,0.25,0.55,0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.25,0.55,0.72,0.44,0.33,0.44,0.25,0.55,0.44,0.5,0.78,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">tions with PDDS increase and mean PDDS increase were com-</text>
   <text y="389.925" x="49.605,54.06,58.011,60.963,64.914,69.369,71.574,76.029,79.485,81.942,86.397,90.852,93.057,99.015,103.47,105.927,108.132,113.091,117.546,122.001,125.952,128.904,132.855,135.06,137.517,141.468,144.924,147.381,150.837,153.042,156.993,161.448,165.903,167.613,174.066,180.519,186.972,192.264,198.717,200.922,203.127,206.079,210.03,213.486,217.941,221.892,225.843,228.3,230.757,235.212,239.163,241.62,245.49" svgx:width="0.5,0.44,0.33,0.44,0.5,0.25,0.5,0.39,0.28,0.5,0.5,0.25,0.67,0.5,0.28,0.25,0.56,0.5,0.5,0.44,0.33,0.44,0.25,0.28,0.44,0.39,0.28,0.39,0.25,0.44,0.5,0.5,0.25,0.72,0.72,0.72,0.72,0.72,0.25,0.25,0.33,0.44,0.39,0.5,0.44,0.44,0.28,0.28,0.5,0.44,0.28,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">pared using Chi Square tests and ANOVA, respectively.</text>
   <text y="400.923" x="49.605,56.013,59.919,63.33,68.244,70.656,73.563,76.974,79.881" svgx:width="0.72,0.44,0.39,0.56,0.28,0.33,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Results: </text>
   <text y="400.923" x="82.779,89.187,93.597,96.504,98.916,103.326,107.736,110.634,115.044,117.942,122.352,126.258,130.164,133.071,136.482,139.38,143.79,148.2,151.098,157.506,162.915,168.162,171.06,173.472,177.882,181.788,184.695,188.601,191.499,197.907,201.813,204.72,208.626,211.524,215.934,220.344,223.242,226.653,229.065,233.475,237.885,240.297,243.204,245.616,249.522,253.428,257.838,260.25,263.148,267.558,269.97,272.715,275.622,279.528,282.264" svgx:width="0.72,0.5,0.33,0.28,0.5,0.5,0.25,0.5,0.25,0.5,0.44,0.44,0.33,0.39,0.25,0.5,0.5,0.25,0.72,0.72,0.61,0.25,0.28,0.5,0.44,0.33,0.44,0.25,0.72,0.44,0.33,0.44,0.25,0.5,0.5,0.25,0.39,0.28,0.5,0.5,0.28,0.33,0.28,0.44,0.44,0.5,0.28,0.25,0.5,0.28,0.33,0.33,0.44,0.33,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">During 2 years on NAT there were no significant differ-</text>
   <text y="411.921" x="49.605,53.511,57.921,61.827,65.733,69.144,71.394,73.122,75.534,79.944,82.194,83.922,88.332,90.744,94.155,98.061,102.471,104.883,107.295,109.707,112.119,116.529,118.779,120.507,124.917,127.824,132.234,136.644,139.551,143.457,146.868,150.279,152.691,157.101,161.511,163.761,165.489,169.899,173.805,176.217,182.625,186.531,190.437,194.847,197.097,198.825,203.235,206.142,210.552,214.962,219.372,222.783,224.943,227.193,228.921,235.329,239.739,243.645,246.552,248.802,250.53,252.942,257.352,261.258,263.508,265.236,269.142,273.552,275.964,278.376,281.283,285.279" svgx:width="0.44,0.5,0.44,0.44,0.39,0.25,0.55,0.28,0.5,0.25,0.55,0.5,0.28,0.39,0.44,0.5,0.28,0.28,0.28,0.28,0.5,0.25,0.55,0.5,0.33,0.5,0.5,0.33,0.44,0.39,0.39,0.28,0.5,0.5,0.25,0.55,0.5,0.44,0.28,0.72,0.44,0.44,0.5,0.25,0.55,0.5,0.33,0.5,0.5,0.5,0.39,0.25,0.25,0.55,0.72,0.5,0.44,0.33,0.25,0.55,0.28,0.5,0.44,0.25,0.55,0.44,0.5,0.28,0.28,0.33,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">ences in disability progression between groups. Over the entire </text>
   <text y="422.919" x="49.605,53.016,55.428,59.838,64.248,68.073,70.233,72.096,79.008,82.914,87.324,89.736,93.642,98.052,99.915,106.827,111.237,115.647,118.059,122.469,125.88,127.743,132.153,135.06,136.923,139.83,144.24,146.652,149.064,153.474,159.882,162.789,167.199,171.609,173.472,176.379,182.787,188.196,193.605,198.591,203.001,207.411,209.823,211.686,216.6,219.507,225.915,230.901,235.311,239.721,242.133,243.996,246.903,253.311,256.722,261.708,266.118,270.528,272.94" svgx:width="0.39,0.28,0.5,0.5,0.5,0.25,0.25,0.78,0.44,0.5,0.28,0.44,0.5,0.25,0.78,0.5,0.5,0.28,0.5,0.39,0.25,0.5,0.33,0.25,0.33,0.5,0.28,0.28,0.5,0.72,0.33,0.5,0.5,0.25,0.33,0.72,0.72,0.61,0.56,0.5,0.5,0.28,0.25,0.56,0.33,0.72,0.56,0.5,0.5,0.28,0.25,0.33,0.72,0.39,0.56,0.5,0.5,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">study, median months of follow-up (NAT=48; FIN=54; INJ=60; </text>
   <text y="422.919" x="274.803" svgx:width="0.61" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">P</text>
   <text y="422.919" x="280.185,285.261" svgx:width="0.56,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">&lt; </text>
   <text y="433.917" x="49.605,54.015,56.175,60.585,64.995,69.405,73.815,76.722,78.972,80.511,84.921,88.827,91.734,94.146,98.052,102.462,104.712,106.251,109.662,112.074,116.484,120.894,123.306,126.213,128.625,132.531,136.437,140.847,143.259,145.671,149.496,151.656,153.906,155.445,158.352,162.762,165.012,166.551,168.963,173.373,177.279,179.529,181.059,185.469,189.879,194.289,198.195,200.607,203.514,207.42,211.83,214.08,215.61,219.516,223.926,227.832,230.244,234.654,238.065,240.477,243.888,246.138,247.677,252.087,255.993,258.9,261.312,263.724,267.63,270.042,274.452,278.358,282.768,285.27" svgx:width="0.5,0.25,0.5,0.5,0.5,0.5,0.33,0.25,0.55,0.5,0.44,0.33,0.28,0.44,0.5,0.25,0.55,0.39,0.28,0.5,0.5,0.28,0.33,0.28,0.44,0.44,0.5,0.28,0.28,0.5,0.25,0.25,0.55,0.33,0.5,0.25,0.55,0.28,0.5,0.44,0.25,0.55,0.5,0.5,0.5,0.44,0.28,0.33,0.44,0.5,0.25,0.55,0.44,0.5,0.44,0.28,0.5,0.39,0.28,0.39,0.25,0.55,0.5,0.44,0.33,0.28,0.28,0.44,0.28,0.5,0.44,0.5,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">0.0001) varied significantly. In the unpaired analysis participant </text>
   <text y="444.915" x="49.605,54.015,56.922,61.332,65.742,70.152,73.059,75.471,77.883,82.293,86.703,90.114,91.788,98.196,100.608,103.02,107.43,109.104,114.018,120.426,126.834,131.748,133.422,135.834,140.244,144.15,147.057,150.963,154.869,158.28,162.186,163.86,166.767,173.175,178.584,183.993,188.979,193.389,197.799,205.206,207.618,209.292,214.206,217.113,223.521,228.507,232.917,237.327,244.734,247.146,248.82,251.727,258.135,261.546,266.532,270.942,275.352,282.759,285.261" svgx:width="0.5,0.33,0.5,0.5,0.5,0.33,0.28,0.28,0.5,0.5,0.39,0.25,0.72,0.28,0.28,0.5,0.25,0.56,0.72,0.72,0.56,0.25,0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.25,0.33,0.72,0.72,0.61,0.56,0.5,0.5,0.83,0.28,0.25,0.56,0.33,0.72,0.56,0.5,0.5,0.83,0.28,0.25,0.33,0.72,0.39,0.56,0.5,0.5,0.83,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">proportions with PDDS increase (NAT=31%; FIN=46%; INJ=42%; </text>
   <text y="455.913" x="49.605" svgx:width="0.61" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">P</text>
   <text y="455.913" x="55.014,60.0,64.41,66.57,70.98,75.39,78.297,80.547,85.578,89.484,93.894,98.304,100.554,105.585,112.497,116.403,120.309,124.719,126.969,132.0,136.914,143.322,149.73,154.644,156.894,161.925,164.337,168.747,172.653,175.56,179.466,183.372,186.783,190.689,192.939,197.97,200.877,207.285,212.694,218.103,223.089,227.499,229.659,234.069,238.479,240.891,243.141,248.172,253.086,255.993,262.401,267.387,271.797,273.957,278.367,282.777,285.279" svgx:width="0.56,0.5,0.25,0.5,0.5,0.33,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.78,0.44,0.44,0.5,0.25,0.55,0.56,0.72,0.72,0.56,0.25,0.55,0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.25,0.55,0.33,0.72,0.72,0.61,0.56,0.5,0.25,0.5,0.5,0.28,0.25,0.55,0.56,0.33,0.72,0.56,0.5,0.25,0.5,0.5,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">=0.02) and mean PDDS increase (NAT=0.31; FIN=0.58; </text>
   <text y="466.911" x="49.605,52.512,58.92,62.331,67.317,71.727,73.887,78.297,82.707,85.119" svgx:width="0.33,0.72,0.39,0.56,0.5,0.25,0.5,0.5,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">INJ=0.71; </text>
   <text y="466.911" x="87.828" svgx:width="0.61" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">P</text>
   <text y="466.911" x="93.237,98.223,102.633,104.793,109.203,113.613,118.023,120.93,123.639,130.047,133.953,136.86,140.766,143.475,146.886,149.298,153.708,158.118,160.53,163.437,165.849,169.755,173.661,178.071,180.483,182.895,187.305,190.014,194.424,196.836,199.581,202.488,206.394,209.301,213.207,217.617,220.029,222.189,224.403,230.811,235.221,239.127,241.287,243.996,248.406,252.312,256.722,261.132,265.038,267.585,269.745,272.454,276.36,280.77,285.27" svgx:width="0.56,0.5,0.25,0.5,0.5,0.5,0.33,0.25,0.72,0.44,0.33,0.44,0.25,0.39,0.28,0.5,0.5,0.28,0.33,0.28,0.44,0.44,0.5,0.28,0.28,0.5,0.25,0.5,0.28,0.33,0.33,0.44,0.33,0.44,0.5,0.28,0.25,0.25,0.72,0.5,0.44,0.25,0.25,0.5,0.44,0.5,0.5,0.44,0.33,0.25,0.25,0.44,0.5,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">=0.004) were significantly different. Age, gender, and </text>
   <text y="477.909" x="49.605,53.016,55.428,59.334,62.241,64.653,67.065,71.475,75.885,77.946,82.86,89.268,95.676,100.59,102.651,109.059,112.965,115.872,119.778,121.839,125.745,129.156,132.567,136.977,140.883,143.295,147.201,149.613,153.519,157.929,159.99,166.398,168.81,171.222,175.632,177.693,181.599,186.009,189.915,194.325,198.735,202.641,204.702,207.114,211.524,213.585,218.499,224.907,231.315,236.229,238.29,241.197,245.103,247.515,249.927" svgx:width="0.39,0.28,0.44,0.33,0.28,0.28,0.5,0.5,0.25,0.56,0.72,0.72,0.56,0.25,0.72,0.44,0.33,0.44,0.25,0.44,0.39,0.39,0.5,0.44,0.28,0.44,0.28,0.44,0.5,0.25,0.72,0.28,0.28,0.5,0.25,0.44,0.5,0.44,0.5,0.5,0.44,0.25,0.28,0.5,0.25,0.56,0.72,0.72,0.56,0.25,0.33,0.44,0.28,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">starting PDDS were associated with change in PDDS (all </text>
   <text y="477.909" x="251.988" svgx:width="0.61" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">P</text>
   <text y="477.909" x="257.415,262.401,264.462,268.872,271.032,275.442,279.852,282.759,285.261" svgx:width="0.56,0.25,0.5,0.25,0.5,0.5,0.33,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">&lt; 0.03); </text>
   <text y="488.907" x="49.605,52.017,56.427,58.839,62.745,65.157,67.182,70.089,74.499,76.911,79.323,83.733,90.141,93.048,97.458,101.868,103.893,106.305,108.717,115.629,119.535,121.56,127.968,131.874,135.285,137.31,141.72,146.13,148.542,150.567" svgx:width="0.28,0.5,0.28,0.44,0.28,0.25,0.33,0.5,0.28,0.28,0.5,0.72,0.33,0.5,0.5,0.25,0.28,0.28,0.78,0.44,0.25,0.72,0.44,0.39,0.25,0.5,0.5,0.28,0.25,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">total follow-up time was not (</text>
   <text y="488.907" x="153.474" svgx:width="0.61" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">P</text>
   <text y="488.907" x="158.874,163.86,168.27,170.43,174.507,178.917,181.824,183.984,186.009,188.916,193.326,195.351,197.763,202.173,206.079,208.104,212.514,216.42,218.832,221.739,225.645,230.055,232.08,238.488,243.897,248.478,251.385,256.299,259.206,265.614,267.639,271.545,275.955,279.861,282.273" svgx:width="0.56,0.5,0.25,0.5,0.5,0.33,0.25,0.25,0.33,0.5,0.25,0.28,0.5,0.44,0.25,0.5,0.44,0.28,0.33,0.44,0.5,0.25,0.72,0.72,0.61,0.33,0.56,0.33,0.72,0.25,0.44,0.5,0.44,0.28,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">=0.11). In the paired NAT-FIN anal-</text>
   <text y="499.905" x="49.605,54.015,57.426,59.838,63.249,65.409,67.659,68.991,73.401,77.811,85.218,87.468,88.8,93.21,96.117,98.367,99.699,106.107,111.516,116.763,119.013,120.345,124.251,128.661,133.071,135.321,136.653,141.063,145.473,152.88,155.13,156.462,160.872,163.779,166.029,167.361,172.275,175.182,181.59,183.84,185.172,189.582,193.488,196.395,198.807,201.219,205.125,207.537,211.947,215.853,220.263,222.675,226.086,228.336,229.668,232.575,236.481,240.891,245.301,248.208,250.62,254.526,258.936,261.186,262.518,267.432,273.84,280.248,285.252" svgx:width="0.5,0.39,0.28,0.39,0.25,0.25,0.55,0.5,0.5,0.83,0.25,0.55,0.5,0.33,0.25,0.55,0.72,0.72,0.61,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.5,0.5,0.83,0.25,0.55,0.5,0.33,0.25,0.55,0.56,0.33,0.72,0.25,0.55,0.5,0.44,0.33,0.28,0.28,0.44,0.28,0.5,0.44,0.5,0.28,0.39,0.25,0.55,0.33,0.44,0.5,0.5,0.33,0.28,0.44,0.5,0.25,0.55,0.56,0.72,0.72,0.56,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">ysis, 24% of NAT and 46% of FIN participants reported PDDS </text>
   <text y="510.903" x="49.605,52.017,56.427,60.333,63.24,67.146,71.052,74.463,78.369,80.871" svgx:width="0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.25,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">increase (</text>
   <text y="510.903" x="83.778" svgx:width="0.61" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">P</text>
   <text y="510.903" x="89.187,94.173,98.583,100.743,105.153,109.563,112.47,114.63,117.132,121.038,125.448,129.858,132.36,139.272,143.178,147.084,151.494,153.996,158.91,165.318,171.726,176.64,179.142,181.554,185.964,189.87,192.777,196.683,200.589,204.0,207.906,210.408,216.816,220.722,224.133,226.635,231.045,233.205,237.615,240.117,243.024,247.434,250.341,252.843,259.251,264.66,269.907,272.409,276.315,280.725,285.225" svgx:width="0.56,0.5,0.25,0.5,0.5,0.33,0.25,0.25,0.44,0.5,0.5,0.25,0.78,0.44,0.44,0.5,0.25,0.56,0.72,0.72,0.56,0.25,0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.25,0.72,0.44,0.39,0.25,0.5,0.25,0.5,0.25,0.33,0.5,0.33,0.25,0.72,0.72,0.61,0.25,0.44,0.5,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">=0.02), and mean PDDS increase was 0.1 for NAT and </text>
   <text y="521.901" x="49.605,54.015,56.175,60.585,62.7,65.607,70.017,72.924,75.039,79.953,82.86,89.268,91.383" svgx:width="0.5,0.25,0.5,0.25,0.33,0.5,0.33,0.25,0.56,0.33,0.72,0.25,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">0.5 for FIN (</text>
   <text y="521.901" x="94.29" svgx:width="0.61" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">P</text>
   <text y="521.901" x="99.708,104.694,109.104,111.264,115.674,120.084,122.991,125.151,127.266,130.173,134.583,136.698,139.11,143.52,147.426,149.541,153.951,157.857,160.269,163.176,167.082,171.492,173.607,180.015,185.424,190.005,192.912,195.819,202.227,205.638,207.753,211.659,216.069,219.975,222.387,226.797,230.208,232.62,236.031,238.191,240.306,244.716,249.126,256.533,258.648,263.058,265.965,268.08,274.488,279.897,285.234" svgx:width="0.56,0.5,0.25,0.5,0.5,0.33,0.25,0.25,0.33,0.5,0.25,0.28,0.5,0.44,0.25,0.5,0.44,0.28,0.33,0.44,0.5,0.25,0.72,0.72,0.61,0.33,0.33,0.72,0.39,0.25,0.44,0.5,0.44,0.28,0.5,0.39,0.28,0.39,0.25,0.25,0.5,0.5,0.83,0.25,0.5,0.33,0.25,0.72,0.72,0.61,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">=0.02). In the paired NAT-INJ analysis, 33% of NAT </text>
   <text y="532.899" x="49.605,53.511,57.921,62.331,64.383,68.793,73.203,80.61,82.662,87.072,89.979,92.031,94.938,101.346,104.757,106.809,111.219,115.125,118.032,120.444,122.856,126.762,129.174,133.584,137.49,141.9,144.312,147.723,149.775,152.682,156.588,160.998,165.408,168.315,170.727,174.633,179.043,181.095,186.009,192.417,198.825,203.739,205.791,208.203,212.613,216.519,219.426,223.332,227.238,230.649,234.555,236.607" svgx:width="0.44,0.5,0.5,0.25,0.5,0.5,0.83,0.25,0.5,0.33,0.25,0.33,0.72,0.39,0.25,0.5,0.44,0.33,0.28,0.28,0.44,0.28,0.5,0.44,0.5,0.28,0.39,0.25,0.33,0.44,0.5,0.5,0.33,0.28,0.44,0.5,0.25,0.56,0.72,0.72,0.56,0.25,0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.25,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">and 47% of INJ participants reported PDDS increase (</text>
   <text y="532.899" x="239.514" svgx:width="0.61" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">P</text>
   <text y="532.899" x="244.941,249.927,254.337,256.497,260.907,265.317,268.224,270.384,272.436,276.342,280.752,285.252" svgx:width="0.56,0.5,0.25,0.5,0.5,0.33,0.25,0.25,0.44,0.5,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">=0.20), and </text>
   <text y="543.897" x="49.605,56.517,60.423,64.329,68.739,70.989,71.7,76.614,83.022,89.43,94.344,96.594,97.305,99.717,104.127,108.033,110.94,114.846,118.752,122.163,126.069,128.31900000000002,129.03,135.438,139.344,142.755,145.005,145.716,150.126,152.286,156.696,158.946,159.657,162.564,166.974,169.881,172.131,172.842,179.25,184.659,189.906,192.156,192.867,196.773,201.183,205.593,207.843,208.554,212.964,215.124,219.534,221.784,222.495,225.402,229.812,232.719,234.969,235.68,238.587,244.995,248.406,250.656,251.367" svgx:width="0.78,0.44,0.44,0.5,0.25,0.55,0.56,0.72,0.72,0.56,0.25,0.55,0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.25,0.55,0.72,0.44,0.39,0.25,0.55,0.5,0.25,0.5,0.25,0.55,0.33,0.5,0.33,0.25,0.55,0.72,0.72,0.61,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.5,0.25,0.5,0.25,0.55,0.33,0.5,0.33,0.25,0.55,0.33,0.72,0.39,0.25,0.55,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">mean PDDS increase was 0.2 for NAT and 0.7 for INJ (</text>
   <text y="543.897" x="254.274" svgx:width="0.61" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">P</text>
   <text y="543.897" x="259.728,264.714,269.124,271.284,275.694,280.104,283.011,285.261" svgx:width="0.56,0.5,0.25,0.5,0.5,0.33,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">=0.06). </text>
   <text y="554.895" x="49.605,55.014,59.424,63.33,65.58,67.929,72.339,74.751,77.496,80.403,84.309,87.216,91.122,95.532,99.438,103.344,106.755,109.005,111.354,113.766,118.176,120.426,122.775,127.185,130.092,134.502,138.912,143.322,146.229,148.641,151.053,155.463,159.873,163.284,165.534,167.883,174.291,176.703,179.115,183.525,185.775,188.124,193.038,199.446,205.854,210.768,213.018,215.367,217.779,222.189,226.095,229.002,232.908,236.814,240.225,244.131,246.381,248.73,252.636,257.046,261.456,263.706,266.055,272.967,276.873,280.779,285.279" svgx:width="0.61,0.5,0.44,0.25,0.55,0.5,0.28,0.33,0.33,0.44,0.33,0.44,0.5,0.44,0.44,0.39,0.25,0.55,0.28,0.5,0.25,0.55,0.5,0.33,0.5,0.5,0.5,0.33,0.28,0.28,0.5,0.5,0.39,0.25,0.55,0.72,0.28,0.28,0.5,0.25,0.55,0.56,0.72,0.72,0.56,0.25,0.55,0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.78,0.44,0.44,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">The differences in proportions with PDDS increase and mean </text>
   <text y="565.893" x="49.605,54.519,60.927,67.335,72.249,74.499,76.038,78.45,82.86,86.766,89.673,93.579,97.485,100.896,104.802,107.052,108.591,114.999,118.905,121.812,125.718,127.968,129.507,133.917,138.327,140.739,142.989,144.528,147.939,150.351,154.257,156.669,159.081,162.492,164.904,167.316,171.222,175.128,177.54,179.952,184.362,186.612,188.151,191.562,193.974,198.384,202.794,205.206,208.113,210.525,214.431,218.337,222.747,225.159,227.409,228.948,231.36,235.77,238.02,239.559,243.465,245.877,248.289,252.699,256.605,259.512,261.762,263.301,267.711,270.618,272.868,274.407,276.819,281.229,285.225" svgx:width="0.56,0.72,0.72,0.56,0.25,0.55,0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.25,0.55,0.72,0.44,0.33,0.44,0.25,0.55,0.5,0.5,0.28,0.25,0.55,0.39,0.28,0.44,0.28,0.28,0.39,0.28,0.28,0.44,0.44,0.28,0.28,0.5,0.25,0.55,0.39,0.28,0.5,0.5,0.28,0.33,0.28,0.44,0.44,0.5,0.28,0.25,0.55,0.28,0.5,0.25,0.55,0.44,0.28,0.28,0.5,0.44,0.33,0.25,0.55,0.5,0.33,0.25,0.55,0.28,0.5,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">PDDS increase were not statistically significant in either of the </text>
   <text y="576.891" x="49.605,56.517,60.423,62.835,66.741,71.151,75.057,79.467,81.627,86.037,88.944,93.354,97.764,102.174,105.585,107.745,111.651,114.558,116.97,120.876,123.783,125.943,129.849,134.259,137.166,140.073,143.979,147.885,150.297,152.709,157.119,161.529,163.689,166.596,171.006,173.913,176.073,182.985,187.395,189.807,192.219,194.631,199.041,201.453,205.359,207.519,211.425,215.835,222.747,227.157,231.063,233.97,236.382,239.793,244.203,248.613,252.024" svgx:width="0.78,0.44,0.28,0.44,0.5,0.44,0.5,0.25,0.5,0.33,0.5,0.5,0.5,0.39,0.25,0.44,0.33,0.28,0.44,0.33,0.25,0.44,0.5,0.33,0.33,0.44,0.44,0.28,0.28,0.5,0.5,0.25,0.33,0.5,0.33,0.25,0.78,0.5,0.28,0.28,0.28,0.5,0.28,0.44,0.25,0.44,0.5,0.78,0.5,0.44,0.33,0.28,0.39,0.5,0.5,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">matched groups after correcting for multiple comparisons.</text>
   <text y="587.889" x="49.605,56.103,60.603,65.607,69.603,72.105,77.109,80.61,83.112,87.612,92.616,96.117,99.114" svgx:width="0.72,0.5,0.56,0.44,0.28,0.56,0.39,0.28,0.5,0.56,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Conclusions: </text>
   <text y="587.889" x="101.526,106.71,109.707,113.703,118.203,121.704,124.206,126.708,129.21,133.71,138.21,140.712,145.212,149.712,152.115,154.617,159.117,161.529,165.525,167.928,172.428,174.93,177.765,180.762,184.758,187.755,191.751,196.251,198.753,201.156,203.658,208.158,212.154,215.151,219.147,223.647,228.147,230.55,234.546,237.543,240.045,244.041,247.038,249.441,253.941,256.353,260.853,264.849,268.845,271.842,275.343,277.746,282.246,285.243" svgx:width="0.61,0.33,0.44,0.5,0.39,0.28,0.28,0.28,0.5,0.5,0.28,0.5,0.5,0.25,0.28,0.5,0.25,0.44,0.25,0.5,0.28,0.33,0.33,0.44,0.33,0.44,0.5,0.28,0.25,0.28,0.5,0.44,0.33,0.44,0.5,0.5,0.25,0.44,0.33,0.28,0.44,0.33,0.25,0.5,0.25,0.5,0.44,0.44,0.33,0.39,0.25,0.5,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">Transitioning to a different therapy after 2 years of </text>
   <text y="598.887" x="49.605,56.103,61.602,66.939,69.297,75.795,79.791,83.292,85.65,89.646,93.147,96.648,101.148,105.144,107.646,111.642,114.144,118.14,122.64,124.998,131.496,133.998,136.5,141.0,143.358,147.354,151.854,154.212,156.714,161.214,165.21,168.207,172.203,176.199,179.7,183.696,188.196,190.554,193.056,195.558,200.058,204.054,206.556,209.058,213.558,218.058,222.558,227.058,229.416,233.916,236.913,239.271,242.772,246.768,249.27,252.267,255.264,258.261,262.257,266.757,271.257,274.254,276.756,280.752,285.252" svgx:width="0.72,0.72,0.61,0.25,0.72,0.44,0.39,0.25,0.44,0.39,0.39,0.5,0.44,0.28,0.44,0.28,0.44,0.5,0.25,0.72,0.28,0.28,0.5,0.25,0.44,0.5,0.25,0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.5,0.25,0.28,0.28,0.5,0.44,0.28,0.28,0.5,0.5,0.5,0.5,0.25,0.5,0.33,0.25,0.39,0.44,0.28,0.33,0.33,0.33,0.44,0.5,0.5,0.33,0.28,0.44,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">NAT was associated with an increased likelihood of self-reported </text>
   <text y="609.885" x="49.605,54.105,56.607,60.108,64.104,68.604,71.106,73.608,76.11,78.612,83.112,85.182,89.682,92.679,97.179,101.679,104.676,108.672,112.173,115.674,118.176,122.676,127.176,129.246,133.242,137.742,142.242,144.312,146.814,151.314,155.31,158.307,162.303,166.299,169.8,173.796,178.296,180.366,187.368,191.364,195.36,199.86,201.93,206.43,208.932,212.433,216.429,220.929,223.431,225.933,228.435,230.937,234.852,237.102,239.172,244.176,246.678,253.68,256.182,258.684,262.68,265.677,267.747,270.744,273.246,277.746,282.246" svgx:width="0.5,0.28,0.39,0.44,0.5,0.28,0.28,0.28,0.28,0.5,0.25,0.5,0.33,0.5,0.5,0.33,0.44,0.39,0.39,0.28,0.5,0.5,0.25,0.44,0.5,0.5,0.25,0.28,0.5,0.44,0.33,0.44,0.44,0.39,0.44,0.5,0.25,0.78,0.44,0.44,0.5,0.25,0.5,0.28,0.39,0.44,0.5,0.28,0.28,0.28,0.28,0.5,0.25,0.25,0.56,0.28,0.78,0.28,0.28,0.44,0.33,0.25,0.33,0.28,0.5,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">disability progression and increased mean disability. Similar find-</text>
   <text y="620.883" x="49.605,52.107,56.607,61.107,64.608,66.858,70.17,76.668,80.664,83.661,87.657,89.907,93.219,97.719,102.219,105.72,109.716,112.713,117.213,121.209,125.709,127.959,131.271,135.771,139.272,141.774,146.274,150.774,153.024,156.336,160.836,163.833,168.333,172.833,176.829,181.329,184.83,187.332,189.834,194.334,196.584,199.896,203.397,207.393,211.893,214.89,218.886,221.136,224.448,228.948,232.944,235.446,238.443,242.439,246.939,249.189,252.501,256.497,260.997,264.993,267.495,271.995,275.496,279.492,282.993,285.243" svgx:width="0.28,0.5,0.5,0.39,0.25,0.55,0.72,0.44,0.33,0.44,0.25,0.55,0.5,0.5,0.39,0.44,0.33,0.5,0.44,0.5,0.25,0.55,0.5,0.39,0.28,0.5,0.5,0.25,0.55,0.5,0.33,0.5,0.5,0.44,0.5,0.39,0.28,0.28,0.5,0.25,0.55,0.39,0.44,0.5,0.33,0.44,0.25,0.55,0.5,0.44,0.28,0.33,0.44,0.5,0.25,0.55,0.44,0.5,0.44,0.28,0.5,0.39,0.44,0.39,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">ings were observed using propensity score paired analyses, </text>
   <text y="631.881" x="49.605,53.601,56.103,58.605,63.105,67.605,72.105,76.605,81.105,83.355,87.036,89.538,94.038,98.034,101.535,105.531,107.781,111.462,115.962,118.464,121.299,124.296,128.292,131.289,135.285,139.785,143.781,147.777,151.278,153.528,157.209,163.707,167.703,170.7,174.696,176.946,180.627,185.127,189.627,192.129,194.379,198.06,201.561,204.063,208.059,210.561,213.063,216.564,219.066,221.568,225.564,229.56,232.062,234.564,239.064,241.314,244.995,248.496,250.998,255.498,259.998,262.5,265.497,267.999,271.995,275.991,280.491,282.993,285.243" svgx:width="0.44,0.28,0.28,0.5,0.5,0.5,0.5,0.5,0.25,0.55,0.28,0.5,0.44,0.39,0.44,0.25,0.55,0.5,0.28,0.33,0.33,0.44,0.33,0.44,0.5,0.44,0.44,0.39,0.25,0.55,0.72,0.44,0.33,0.44,0.25,0.55,0.5,0.5,0.28,0.25,0.55,0.39,0.28,0.44,0.28,0.28,0.39,0.28,0.28,0.44,0.44,0.28,0.28,0.5,0.25,0.55,0.39,0.28,0.5,0.5,0.28,0.33,0.28,0.44,0.44,0.5,0.28,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">although these differences were not statistically significant. </text>
   <text y="642.879" x="49.605,56.103,60.603,65.103,67.605,70.107,72.609,77.109,81.609,85.605,88.107,90.357,91.32,94.821,97.323,101.823,106.323,108.825,112.821,116.322,118.572,119.535,123.531,126.528,130.524,132.774,133.737,138.237,142.233,146.229,150.729,154.725,159.225,161.475,162.438,164.94,169.44,171.69,172.653,176.649,181.149,188.151,192.651,196.647,199.644,203.64,205.89,206.853,209.355,213.855,217.851,220.101,221.064,225.06,227.562,230.064,234.564,237.066,241.062,245.058,247.56,249.81,250.773,255.273,259.773,262.275,266.271,270.771,277.773,281.769,285.27" svgx:width="0.72,0.5,0.5,0.28,0.28,0.28,0.5,0.5,0.44,0.28,0.25,0.55,0.39,0.28,0.5,0.5,0.28,0.44,0.39,0.25,0.55,0.44,0.33,0.44,0.25,0.55,0.5,0.44,0.44,0.5,0.44,0.5,0.25,0.55,0.28,0.5,0.25,0.55,0.44,0.5,0.78,0.5,0.44,0.33,0.44,0.25,0.55,0.28,0.5,0.44,0.25,0.55,0.44,0.28,0.28,0.5,0.28,0.44,0.44,0.28,0.25,0.55,0.5,0.5,0.28,0.44,0.5,0.78,0.44,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">Additional studies are needed to compare the clinical outcomes </text>
   <text y="653.877" x="49.605,53.601,57.102,60.603,65.103,69.099,71.601,75.597,78.099,82.095,86.595,88.845,95.343,97.845,100.347,104.847,107.097,109.599,112.596,116.592,121.092,124.593,127.095,129.597,132.099,136.599,141.099,143.601,148.101,152.601,154.851,157.353,160.35,164.346,168.342,170.844,177.846,181.842,186.342,188.844,191.094,195.09,198.087,200.589,204.585,207.582,209.832,214.332,216.582,221.082,225.078,229.074,232.071,235.572,237.822,242.322,245.319,247.569,254.067,259.566,264.399" svgx:width="0.44,0.39,0.39,0.5,0.44,0.28,0.44,0.28,0.44,0.5,0.25,0.72,0.28,0.28,0.5,0.25,0.28,0.33,0.44,0.5,0.39,0.28,0.28,0.28,0.5,0.5,0.28,0.5,0.5,0.25,0.28,0.33,0.44,0.44,0.28,0.78,0.44,0.5,0.28,0.25,0.44,0.33,0.28,0.44,0.33,0.25,0.5,0.25,0.5,0.44,0.44,0.33,0.39,0.25,0.5,0.33,0.25,0.72,0.72,0.61,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">associated with transitioning treatment after 2 years of NAT.</text>
   <text y="680.877" x="49.605,55.104,59.604,64.104" svgx:width="0.61,0.5,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">P880</text>
   <text y="691.875" x="49.605,58.101,62.601,67.605,72.105,76.605,80.601,88.098,92.094,97.098,100.095,102.345,106.845,109.842,112.092,114.594,119.598,122.595,127.599,131.1,133.602,138.102,143.106,146.103,150.603,154.104,157.605,162.105,166.101,168.603,173.103,176.1,180.096,185.1,187.35,191.346,195.342,199.842,203.838,206.835,209.337,213.837,218.841,222.342,224.592,227.094,232.098" svgx:width="0.94,0.5,0.56,0.5,0.5,0.44,0.83,0.44,0.56,0.33,0.25,0.5,0.33,0.25,0.28,0.56,0.33,0.56,0.39,0.28,0.5,0.56,0.33,0.5,0.39,0.39,0.5,0.44,0.28,0.5,0.33,0.44,0.56,0.25,0.44,0.44,0.5,0.44,0.33,0.28,0.5,0.56,0.39,0.25,0.28,0.56,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Management of infusion-associated reactions in </text>
   <text y="702.873" x="49.605,54.105,56.607,60.603,68.1,71.097,76.101,80.097,85.101,92.598,97.098,102.102,105.099,108.096,112.092,116.088,120.588,123.585,127.581,132.585,134.835,138.831,142.827,145.329,149.829,154.833,158.334,160.836,165.84,170.34,173.337,177.333,181.329,188.826,191.328,194.325,197.322,199.824,204.828,209.328,211.578,219.075,224.079,226.581,229.578,232.08,237.084,239.586,243.582" svgx:width="0.5,0.28,0.44,0.83,0.33,0.56,0.44,0.56,0.83,0.5,0.56,0.33,0.33,0.44,0.44,0.5,0.33,0.44,0.56,0.25,0.44,0.44,0.28,0.5,0.56,0.39,0.28,0.56,0.5,0.33,0.44,0.44,0.83,0.28,0.33,0.33,0.28,0.56,0.5,0.25,0.83,0.56,0.28,0.33,0.28,0.56,0.28,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">alemtuzumab-treated relapsing-remitting multiple </text>
   <text y="713.871" x="49.605,53.106,57.102,59.604,63.6,67.596,72.096,75.597,78.099,81.6,83.85,88.854,93.354,96.351,98.853,102.849,107.853,110.85" svgx:width="0.39,0.44,0.28,0.44,0.44,0.5,0.39,0.28,0.39,0.25,0.56,0.5,0.33,0.28,0.44,0.56,0.33,0.39" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">sclerosis patients</text>
   <text y="724.869" x="49.605,55.104,57.354,65.355,69.351,73.851,77.847" svgx:width="0.61,0.25,0.89,0.44,0.5,0.44,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">L Mayer</text>
   <text y="722.439" x="80.845" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="724.959" x="83.77,86.02,88.27,93.769,96.019,102.022,106.018,109.519,113.515,118.015" svgx:width="0.25,0.25,0.61,0.25,0.67,0.44,0.39,0.44,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, L Casady</text>
   <text y="722.439" x="122.514" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">2</text>
   <text y="724.959" x="125.439,127.689,129.939,136.437,138.687,144.69,147.192,151.188,155.688,158.19,162.69" svgx:width="0.25,0.25,0.72,0.25,0.67,0.28,0.44,0.5,0.28,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, G Clayton</text>
   <text y="722.439" x="167.19" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">3</text>
   <text y="724.959" x="170.115,172.365,174.615,179.619,181.869,188.367,192.867,197.367,201.363,203.865" svgx:width="0.25,0.25,0.56,0.25,0.72,0.5,0.5,0.44,0.28,0.44" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, P Oyuela</text>
   <text y="722.439" x="207.861" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">4</text>
   <text y="724.959" x="210.786,213.036,215.286,221.784,228.282,230.532,238.533,242.529,245.526,250.026,254.526,257.028,259.53" svgx:width="0.25,0.25,0.72,0.72,0.25,0.89,0.44,0.33,0.5,0.5,0.28,0.28,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, DH Margolin</text>
   <text y="722.439" x="264.029" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">4</text>
   <text y="724.959" x="266.954,269.204" svgx:width="0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, </text>
   <text y="735.957" x="49.604,54.104,58.604,60.854,65.354,69.35,73.85,77.846,80.348,83.345,85.595,90.095,93.092,95.342,97.844,102.344,106.34,108.59,114.593,121.091,127.094,132.593,135.59,143.591,148.595,150.845,153.842,156.092,160.088,164.588,169.088,171.338,174.335,177.332,179.582,182.579,187.079,191.579,195.575,199.076,201.578,204.08,208.58,212.576,215.078,219.578,222.575" svgx:width="0.5,0.5,0.25,0.5,0.44,0.5,0.44,0.28,0.33,0.25,0.5,0.33,0.25,0.28,0.5,0.44,0.25,0.67,0.72,0.67,0.61,0.33,0.89,0.56,0.25,0.33,0.25,0.44,0.5,0.5,0.25,0.33,0.33,0.25,0.33,0.5,0.5,0.44,0.39,0.28,0.28,0.5,0.44,0.28,0.5,0.33,0.39" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">on behalf of the CARE-MS I and II Investigators</text>
  </g>
  <path style="fill:none;stroke:rgb(0,0,0);stroke-width:0.44;" d="M297.260 715.310 L332.500 715.310 "/>
  <g begin="text">
   <text y="74.592" x="297.26" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">1</text>
   <text y="77.112" x="300.36,306.633,310.899,315.669,318.441,322.212,326.982,329.754,332.274,337.548,341.814,346.08,350.85,354.621,357.141,363.414,367.68,372.45,376.221,380.991,383.763,388.533,393.303,397.569,400.089,406.362,411.132,415.902,419.673,424.443,427.215,429.987,434.757,439.527,442.299,446.07,448.59,451.11,458.877,463.647,466.167,472.44,475.212,477.984,482.754,485.526,489.792,492.312,497.082,499.854,502.374,508.647,512.913,517.683,520.455,524.226,528.996,531.498" svgx:width="0.67,0.44,0.5,0.28,0.39,0.5,0.28,0.25,0.56,0.44,0.44,0.5,0.39,0.25,0.67,0.44,0.5,0.39,0.5,0.28,0.5,0.5,0.44,0.25,0.67,0.5,0.5,0.39,0.5,0.28,0.28,0.5,0.5,0.28,0.39,0.25,0.25,0.83,0.5,0.25,0.67,0.28,0.28,0.5,0.28,0.44,0.25,0.5,0.28,0.25,0.67,0.44,0.5,0.28,0.39,0.5,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Central Texas Neurology Consultants, MS Clinic of Central </text>
   <text y="88.11" x="297.264,302.538,306.804,311.07,315.84,319.611,322.131,324.651,330.42,335.19,339.96,344.73,349.5,352.02,357.789,362.559,366.825,371.091,373.611,376.131,381.405,387.174,389.694,392.214,398.982,403.752,406.524,409.296,413.562,418.332,420.852,425.622,428.394,433.164,435.936,440.202,443.973,446.493" svgx:width="0.56,0.44,0.44,0.5,0.39,0.25,0.25,0.61,0.5,0.5,0.5,0.5,0.25,0.61,0.5,0.44,0.44,0.25,0.25,0.56,0.61,0.25,0.25,0.72,0.5,0.28,0.28,0.44,0.5,0.25,0.5,0.28,0.5,0.28,0.44,0.39,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Texas, Round Rock, TX, United States, </text>
   <text y="85.592" x="449.008" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">2</text>
   <text y="88.112" x="452.108,458.876,463.646,466.418,470.684,474.95,478.721,482.492,485.264,488.036,492.302,494.822,499.592,502.364,504.884,509.654,514.424,519.194,521.966,526.466" svgx:width="0.72,0.5,0.28,0.44,0.44,0.39,0.39,0.28,0.28,0.44,0.25,0.5,0.28,0.25,0.5,0.5,0.5,0.28,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">University of South </text>
   <text y="99.11" x="297.263,303.032,305.804,310.574,314.345,317.117,321.887,326.657,329.177,331.697,336.971,341.741,348.509,353.279,358.049,360.569,363.089,368.858,374.132,376.652,379.172,385.94,390.71,393.482,396.254,400.52,405.29,407.81,412.58,415.352,420.122,422.894,427.16,430.931,433.451" svgx:width="0.61,0.28,0.5,0.39,0.28,0.5,0.5,0.25,0.25,0.56,0.5,0.72,0.5,0.5,0.25,0.25,0.61,0.56,0.25,0.25,0.72,0.5,0.28,0.28,0.44,0.5,0.25,0.5,0.28,0.5,0.28,0.44,0.39,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Florida, Tampa, FL, United States, </text>
   <text y="96.592" x="435.967" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">3</text>
   <text y="99.112" x="439.068,445.836,450.102,452.874,457.139,461.909,464.429,471.197,475.967,479.738,484.508,489.278,496.046,498.566,504.839,509.105,513.875,516.647,520.418,524.684,526.934" svgx:width="0.72,0.44,0.28,0.44,0.5,0.25,0.72,0.5,0.39,0.5,0.5,0.72,0.25,0.67,0.44,0.5,0.28,0.39,0.44,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Helen Durham Centre, </text>
   <text y="110.11" x="297.263,304.031,308.801,311.573,315.839,320.105,323.876,327.647,330.419,333.191,337.457,339.977,346.745,351.515,355.286,360.056,362.828,365.6,370.37,373.142,375.662,380.432,383.204,385.724,393.491,398.261,401.033,405.299,409.07,411.59,414.11,420.383,425.153,428.924,433.694,436.466,439.238,442.01,444.53,447.05,453.818,458.588,461.36,464.132,468.398,473.168,475.688,481.961,484.733,489.503,494.273,499.043,503.813,510.581,512.831" svgx:width="0.72,0.5,0.28,0.44,0.44,0.39,0.39,0.28,0.28,0.44,0.25,0.72,0.5,0.39,0.5,0.28,0.28,0.5,0.28,0.25,0.5,0.28,0.25,0.83,0.5,0.28,0.44,0.39,0.25,0.25,0.67,0.5,0.39,0.5,0.28,0.28,0.28,0.25,0.25,0.72,0.5,0.28,0.28,0.44,0.5,0.25,0.67,0.28,0.5,0.5,0.5,0.5,0.72,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">University Hospital of Wales, Cardiff, United Kingdom, </text>
   <text y="118.592" x="297.26" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">4</text>
   <text y="121.112" x="300.36,307.128,311.394,316.164,319.935,324.201,330.969,335.235,337.755,340.275,345.045,347.565,352.335,357.105,361.875,366.645,369.417,372.189,374.709,380.982,385.752,392.52,397.29,402.06,406.83,411.096,413.616,416.136,422.409,427.179,433.947,438.717,442.488,445.26,450.03,454.8,459.066,461.586,464.106,471.873,477.642,480.162,482.682,489.45,494.22,496.992,499.764,504.03,508.53" svgx:width="0.72,0.44,0.5,0.39,0.44,0.72,0.44,0.25,0.25,0.5,0.25,0.5,0.5,0.5,0.5,0.28,0.28,0.25,0.67,0.5,0.72,0.5,0.5,0.5,0.44,0.25,0.25,0.67,0.5,0.72,0.5,0.39,0.28,0.5,0.5,0.44,0.25,0.25,0.83,0.61,0.25,0.25,0.72,0.5,0.28,0.28,0.44,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Genzyme, a Sanofi Company, Cambridge, MA, United </text>
   <text y="132.11" x="297.264,302.034,304.806,309.576,312.348,316.614" svgx:width="0.5,0.28,0.5,0.28,0.44,0.39" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">States</text>
   <text y="159.11" x="297.264,303.267,307.767,311.763,316.767,321.267,325.101,329.601,334.605,339.609,344.613,347.61" svgx:width="0.67,0.5,0.44,0.56,0.5,0.44,0.5,0.56,0.56,0.56,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Background: </text>
   <text y="159.11" x="350.526,357.024,359.526,363.522,370.524,373.026,377.526,381.522,386.022,393.024,397.02,401.52,403.77,406.686,410.682,413.598,418.098,422.598,429.6,433.596,438.096,440.598,444.594,448.59,453.09,456.006,463.008,467.508,472.008,476.508,480.504,483.006,487.506,492.006,496.002,498.504,501.42,505.416,509.916,512.418,514.92,519.42,523.92,528.42,532.92" svgx:width="0.72,0.28,0.44,0.78,0.28,0.5,0.44,0.5,0.78,0.44,0.5,0.25,0.25,0.44,0.25,0.5,0.5,0.78,0.44,0.5,0.28,0.44,0.44,0.5,0.25,0.78,0.5,0.5,0.5,0.44,0.28,0.5,0.5,0.44,0.28,0.25,0.44,0.5,0.28,0.28,0.5,0.5,0.5,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">Alemtuzumab, a humanized monoclonal antibody </text>
   <text y="170.108" x="297.264,301.764,304.266,307.263,311.259,315.255,317.757,321.753,326.253,328.593,332.589,337.089,341.085,343.587,348.087,351.588,354.09,356.439,362.442,368.94,373.44,377.94,380.19,382.539,385.041,388.542,390.891,394.887,399.387,403.887,406.884,411.384,415.884,419.88,424.38,426.72,429.222,433.722,436.071,440.571,445.071,449.067,452.064,454.413,458.913,463.413,465.762,469.758,474.258,478.758,483.258,485.76,488.757,491.259,495.255,498.756,501.105,504.102,508.602,511.599,513.94,516.442,519.439,523.435,527.43,529.932" svgx:width="0.5,0.28,0.33,0.44,0.44,0.28,0.44,0.5,0.25,0.44,0.5,0.44,0.28,0.5,0.39,0.28,0.25,0.67,0.72,0.5,0.5,0.25,0.25,0.28,0.39,0.25,0.44,0.5,0.5,0.33,0.5,0.5,0.44,0.5,0.25,0.28,0.5,0.25,0.5,0.5,0.44,0.33,0.25,0.5,0.5,0.25,0.44,0.5,0.5,0.5,0.28,0.33,0.28,0.44,0.39,0.25,0.33,0.5,0.33,0.25,0.28,0.33,0.44,0.44,0.28,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">directed against CD52, is approved in over 30 countries for treat-</text>
   <text y="181.106" x="297.264,304.266,308.262,312.762,315.264,317.514,324.642,329.142,332.139,334.389,341.517,344.514,348.51,351.012,355.008,359.508,363.009,365.511,370.011,374.511,377.508,380.505,384.501,391.503,394.005,396.507,399.009,401.511,406.011,410.511,412.761,419.889,426.891,431.391,433.893,436.395,438.897,443.397,445.9,449.896,452.146,459.273,462.775,466.771,469.273,473.269,476.266,480.766,484.267,486.769,490.27,492.52,499.648,502.645,508.648,514.651,522.652,527.656,530.653,532.903" svgx:width="0.78,0.44,0.5,0.28,0.25,0.55,0.5,0.33,0.25,0.55,0.33,0.44,0.28,0.44,0.5,0.39,0.28,0.5,0.5,0.33,0.33,0.44,0.78,0.28,0.28,0.28,0.28,0.5,0.5,0.25,0.55,0.78,0.5,0.28,0.28,0.28,0.5,0.28,0.44,0.25,0.55,0.39,0.44,0.28,0.44,0.33,0.5,0.39,0.28,0.39,0.25,0.55,0.33,0.67,0.67,0.89,0.56,0.33,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">ment of relapsing-remitting multiple sclerosis (RRMS). </text>
   <text y="192.104" x="297.264,303.762,306.264,310.26,317.262,319.764,324.264,328.26,332.76,339.762,343.758,348.258,350.931,355.431,359.427,366.429,370.929,375.429,378.93,381.432,384.429,388.425,390.927,394.923,399.423,402.096,405.597,410.097,414.597,418.593,421.59,424.092,428.592,431.589,434.262,438.258,441.093,444.09,446.592,450.589,454.585,458.581,463.081,465.754,470.254,474.754,478.75,481.747,484.42,487.921,492.421,496.921,500.917,505.417,507.919,511.915,516.415,520.411,524.911,529.411,532.911" svgx:width="0.72,0.28,0.44,0.78,0.28,0.5,0.44,0.5,0.78,0.44,0.5,0.25,0.5,0.44,0.78,0.5,0.5,0.39,0.28,0.33,0.44,0.28,0.44,0.5,0.25,0.39,0.5,0.5,0.44,0.33,0.28,0.5,0.33,0.25,0.44,0.33,0.33,0.28,0.44,0.44,0.44,0.5,0.25,0.5,0.5,0.44,0.33,0.25,0.39,0.5,0.5,0.44,0.5,0.28,0.44,0.5,0.44,0.5,0.5,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">Alemtuzumab demonstrated superior efficacy over subcutaneous </text>
   <text y="203.102" x="297.264,299.766,304.266,306.768,310.764,313.761,316.758,320.754,323.751,328.251,332.751,335.001,335.901,340.401,344.397,346.899,350.895,353.892,358.392,362.388,364.638,365.538,369.534,374.034,378.534,380.784,381.684,388.686,392.682,397.182,401.178,405.678,409.674,413.67,418.17,420.672,424.668,426.918,427.818,431.319,435.315,438.312,442.308,444.81,449.31,451.56,452.46,454.962,459.462,461.712,462.612,465.114,469.614,473.61,475.86,476.76,481.26,484.257,488.757,492.753,496.749,499.386,501.636,503.886,504.786,509.286,513.786,517.782,521.283,525.279,527.529,528.429,532.929" svgx:width="0.28,0.5,0.28,0.44,0.33,0.33,0.44,0.33,0.5,0.5,0.25,0.55,0.5,0.44,0.28,0.44,0.33,0.5,0.44,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.78,0.44,0.5,0.44,0.5,0.44,0.44,0.5,0.28,0.44,0.25,0.55,0.39,0.44,0.33,0.44,0.28,0.5,0.25,0.55,0.28,0.5,0.25,0.55,0.28,0.5,0.44,0.25,0.55,0.5,0.33,0.5,0.44,0.44,0.33,0.25,0.25,0.55,0.5,0.5,0.44,0.39,0.44,0.25,0.55,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">interferon beta-1a and manageable safety in the 2-year, phase 3 </text>
   <text y="214.1" x="297.264,303.267,309.765,315.768,321.267,324.264,332.265,337.269,339.978,342.975,345.684,349.68,354.18,358.68,361.389,364.386,367.383,370.092,373.593,376.095,380.595,385.095,387.597,391.593,395.094,397.344,400.053,403.05,407.55,410.547,415.047,418.548,421.05,425.55,430.05,433.047,437.043,440.544,444.045,448.545,452.541,455.043,459.039,461.542,465.538,470.038,472.747,475.744,479.74,483.736,487.732,490.234,492.736,497.236,501.736,505.237,507.946,510.943,513.94,520.438,526.441,529.942,532.939" svgx:width="0.67,0.72,0.67,0.61,0.33,0.89,0.56,0.25,0.33,0.25,0.44,0.5,0.5,0.25,0.33,0.33,0.25,0.39,0.28,0.5,0.5,0.28,0.44,0.39,0.25,0.25,0.33,0.5,0.33,0.5,0.39,0.28,0.5,0.5,0.33,0.44,0.39,0.39,0.5,0.44,0.28,0.44,0.28,0.44,0.5,0.25,0.33,0.44,0.44,0.44,0.28,0.28,0.5,0.5,0.39,0.25,0.33,0.33,0.72,0.67,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">CARE-MS I and II studies. Infusion-associated reactions (IARs) </text>
   <text y="225.098" x="297.264,303.762,307.758,310.755,314.751,317.001,318.279,320.781,325.281,329.277,331.527,332.805,339.807,344.307,347.808,350.31,352.56,353.838,357.834,362.334,369.336,376.338,380.838,385.338,387.588,388.866,391.368,394.365,398.361,402.357,404.859,411.861,415.857,420.357,422.859,425.857,428.854,432.85,435.352,439.348,441.85,445.846,450.346,452.596,453.874,457.87,462.37,466.87,470.866,473.863,477.364,481.36,483.61,484.888,488.884,493.384,497.38,501.88,504.382,507.883,510.133,511.411,514.408,520.906,526.405,529.906,532.903" svgx:width="0.72,0.44,0.33,0.44,0.25,0.55,0.28,0.5,0.44,0.25,0.55,0.78,0.5,0.39,0.28,0.25,0.55,0.44,0.5,0.78,0.78,0.5,0.5,0.25,0.55,0.28,0.33,0.44,0.44,0.28,0.78,0.44,0.5,0.28,0.33,0.33,0.44,0.28,0.44,0.28,0.44,0.5,0.25,0.55,0.44,0.5,0.5,0.44,0.33,0.39,0.44,0.25,0.55,0.44,0.5,0.44,0.5,0.28,0.39,0.25,0.55,0.33,0.72,0.61,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">were the most common treatment-related adverse events (AEs) </text>
   <text y="236.096" x="297.264,301.764,306.264,309.261,311.763,316.263,320.763,323.013,327.009,329.511,332.013,336.513,339.015,343.011,347.007,349.509,351.759,356.259,360.255,364.755,368.751,371.253,375.753,380.253,387.255,391.251,395.751,398.253" svgx:width="0.5,0.5,0.33,0.28,0.5,0.5,0.25,0.44,0.28,0.28,0.5,0.28,0.44,0.44,0.28,0.25,0.5,0.44,0.5,0.44,0.28,0.5,0.5,0.78,0.44,0.5,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">during clinical development.</text>
   <text y="247.094" x="297.264,304.266,309.27,312.267,316.263,320.259,323.256,325.758,330.258,334.254,337.755,340.752" svgx:width="0.78,0.56,0.33,0.44,0.44,0.33,0.28,0.5,0.44,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Objectives: </text>
   <text y="247.094" x="344.946,349.815,354.315,356.565,358.509,361.506,365.502,370.002,374.502,377.499,380.001,382.251,384.195,386.697,391.197,395.193,397.695,402.195,406.191,410.691,414.687,418.683,420.933,422.877,426.873,431.373,435.873,438.123,440.067,443.568,447.564,452.064,456.06,459.057,461.559,464.061,468.561,470.811,472.755,477.255,480.252,482.502,484.446,488.442,490.944,494.94,501.942,504.444,508.944,512.94,517.44,524.442,528.438,532.938" svgx:width="0.61,0.5,0.25,0.55,0.33,0.44,0.5,0.5,0.33,0.28,0.25,0.55,0.28,0.5,0.44,0.28,0.5,0.44,0.5,0.44,0.44,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.39,0.44,0.5,0.44,0.33,0.28,0.28,0.5,0.25,0.55,0.5,0.33,0.25,0.55,0.44,0.28,0.44,0.78,0.28,0.5,0.44,0.5,0.78,0.44,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">To report incidence and severity of alemtuzumab </text>
   <text y="258.092" x="297.264,300.261,306.759,312.762,316.263,318.513,319.314,323.814,328.314,331.311,333.813,338.313,342.813,345.063,345.864,350.364,353.361,357.861,361.857,365.853,368.85,371.1,371.901,374.898,379.398,381.9,384.402,388.902,395.4,398.397,402.897,407.397,409.647,410.448,414.948,417.945,420.195,420.996,423.498,427.998,431.994,434.244,435.045,439.545,444.045,448.545,451.047,455.043,459.543,461.793,462.594,468.597,475.095,481.098,486.597,489.594,497.595,502.599,504.849,505.65,509.151,511.653,516.153,520.653,523.155,527.151,530.652,532.902" svgx:width="0.33,0.72,0.67,0.39,0.25,0.55,0.5,0.5,0.33,0.28,0.5,0.5,0.25,0.55,0.5,0.33,0.5,0.44,0.44,0.33,0.25,0.55,0.33,0.5,0.28,0.28,0.5,0.72,0.33,0.5,0.5,0.25,0.55,0.5,0.33,0.25,0.55,0.28,0.5,0.44,0.25,0.55,0.5,0.5,0.5,0.28,0.44,0.5,0.25,0.55,0.67,0.72,0.67,0.61,0.33,0.89,0.56,0.25,0.55,0.39,0.28,0.5,0.5,0.28,0.44,0.39,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">IARs during 3-year follow-up of the pooled CARE-MS studies, </text>
   <text y="269.09" x="297.264,301.26,305.76,310.26,312.51,315.012,319.512,321.762,326.262,328.764,332.265,336.261,340.761,344.262,347.763,350.013,353.01,359.508,365.511,367.761,374.763,378.759,383.259,387.255,391.755,395.751,402.753,406.749,411.249,413.751,416.001,420.501,423.498,427.494,431.49,433.992,436.494,440.49,444.486,447.987" svgx:width="0.44,0.5,0.5,0.25,0.28,0.5,0.25,0.5,0.28,0.39,0.44,0.5,0.39,0.39,0.25,0.33,0.72,0.67,0.25,0.78,0.44,0.5,0.44,0.5,0.44,0.78,0.44,0.5,0.28,0.25,0.5,0.33,0.44,0.44,0.28,0.28,0.44,0.44,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">and to discuss IAR management practices.</text>
   <text y="280.088" x="297.264,305.76,309.756,312.753,317.757,322.257,327.261,330.762,333.759" svgx:width="0.94,0.44,0.33,0.56,0.5,0.56,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Methods: </text>
   <text y="280.088" x="337.368,342.372,346.368,348.87,351.372,355.368,359.868,362.37,365.871,368.121,369.48,375.978,378.48,380.982,385.482,387.732,389.091,395.094,401.097,409.098,414.102,416.352,417.711,420.708,423.21,426.207,430.203,434.199,436.701,443.703,447.699,452.199,454.701,457.698,462.198,466.194,468.696,473.196,477.192,479.442,480.801,483.798,489.801,496.299,502.302,507.801,510.798,518.799,523.803,526.053,527.412,530.409,532.911" svgx:width="0.56,0.44,0.28,0.28,0.44,0.5,0.28,0.39,0.25,0.55,0.72,0.28,0.28,0.5,0.25,0.55,0.67,0.67,0.89,0.56,0.25,0.55,0.33,0.28,0.33,0.44,0.44,0.28,0.78,0.44,0.5,0.28,0.33,0.5,0.44,0.28,0.5,0.44,0.25,0.55,0.33,0.67,0.72,0.67,0.61,0.33,0.89,0.56,0.25,0.55,0.33,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">Patients with RRMS (treatment-naive [CARE-MS I; </text>
   <text y="291.086" x="297.264,303.762,309.765,315.264,319.764,324.264,328.764,333.264,337.764,342.264,346.764,351.264,354.261,356.286,360.786,363.783,365.808,372.306,376.806,381.306,383.331,387.831,391.827,396.327,398.352,401.349,405.345,407.847,411.843,416.343,419.844,423.84,428.34,430.365,434.865,439.365,441.39,445.89,448.887,451.389,455.889,458.886,460.911,463.413,467.913,471.909,474.906,478.902,483.402,487.902,489.927,492.924,498.927,505.425,511.428,516.927,519.924,527.925,532.929" svgx:width="0.72,0.67,0.61,0.5,0.5,0.5,0.5,0.5,0.5,0.5,0.5,0.33,0.25,0.5,0.33,0.25,0.72,0.5,0.5,0.25,0.5,0.44,0.5,0.25,0.33,0.44,0.28,0.44,0.5,0.39,0.44,0.5,0.25,0.5,0.5,0.25,0.5,0.33,0.28,0.5,0.33,0.25,0.28,0.5,0.44,0.33,0.44,0.5,0.5,0.25,0.33,0.67,0.72,0.67,0.61,0.33,0.89,0.56,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">NCT00530348] or who had relapsed on prior therapy [CARE-MS </text>
   <text y="302.084" x="297.264,300.261,303.258,305.76,308.01,310.206,316.704,322.707,328.206,332.706,337.206,341.706,346.206,350.706,355.206,359.706,364.206,367.203,370.2,372.45,374.646,377.643,381.639,385.635,389.631,392.133,396.633,400.629,405.129,407.379,409.575,412.077,416.577,419.079,422.076,426.072,430.572,434.568,439.068,443.568,448.068,451.569,453.819,456.015,458.517,463.017,466.014,470.514,474.015,476.517,481.017,485.517,489.018,491.268,493.465,497.965,500.962,503.212,505.408,509.404,511.906,515.902,522.904,525.406,529.906" svgx:width="0.33,0.33,0.28,0.25,0.55,0.72,0.67,0.61,0.5,0.5,0.5,0.5,0.5,0.5,0.5,0.5,0.33,0.33,0.25,0.55,0.33,0.44,0.44,0.44,0.28,0.5,0.44,0.5,0.25,0.55,0.28,0.5,0.28,0.33,0.44,0.5,0.44,0.5,0.5,0.5,0.39,0.25,0.55,0.28,0.5,0.33,0.5,0.39,0.28,0.5,0.5,0.39,0.25,0.55,0.5,0.33,0.25,0.55,0.44,0.28,0.44,0.78,0.28,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">II; NCT00548405]) received intravenous infusions of alemtu-</text>
   <text y="313.082" x="297.264,301.26,305.76,312.762,316.758,321.258,323.319,327.819,332.319,334.38,341.382,345.882,348.384,352.884,356.88,361.38,363.441,367.941,372.441,374.502,379.002,381.063,385.059,389.559,394.059,397.56,401.556,405.552,410.052,412.554,415.056,419.556,423.552,425.604,430.104,434.1,438.6,442.101,444.162,448.158,450.66,452.721,457.221,461.217,464.718,468.714,471.216,473.718,478.218,482.214,484.275,488.271,492.771,497.271,499.332,503.832,508.332,510.393,514.893,516.954,520.95,525.45,529.95" svgx:width="0.44,0.5,0.78,0.44,0.5,0.25,0.5,0.5,0.25,0.78,0.5,0.28,0.5,0.44,0.5,0.25,0.5,0.5,0.25,0.5,0.25,0.44,0.5,0.5,0.39,0.44,0.44,0.5,0.28,0.28,0.5,0.44,0.25,0.5,0.44,0.5,0.39,0.25,0.44,0.28,0.25,0.5,0.44,0.39,0.44,0.28,0.28,0.5,0.44,0.25,0.44,0.5,0.5,0.25,0.5,0.5,0.25,0.5,0.25,0.44,0.5,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">zumab 12 mg/day on 5 consecutive days at baseline and on 3 con-</text>
   <text y="324.08" x="297.264,300.765,304.761,308.757,313.257,315.759,318.261,322.761,326.757,329.007,332.301,336.801,340.797,345.297,348.798,351.048,354.342,358.842,363.342,365.592,368.886,375.888,380.388,384.888,387.39,391.89,395.391,397.641,400.935,403.437,407.433,409.935,413.931,416.568,418.818,421.068,424.362,428.358,432.858,437.358,439.608,442.902,446.898,450.399,453.396,457.896,461.892,465.888,470.388,474.384,478.884,481.134,484.428,488.424,490.927,494.923,501.925,504.427,508.927,512.923,517.423,524.425,528.421,532.921" svgx:width="0.39,0.44,0.44,0.5,0.28,0.28,0.5,0.44,0.25,0.55,0.5,0.44,0.5,0.39,0.25,0.55,0.5,0.5,0.25,0.55,0.78,0.5,0.5,0.28,0.5,0.39,0.25,0.55,0.28,0.44,0.28,0.44,0.33,0.25,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.44,0.39,0.33,0.5,0.44,0.44,0.5,0.44,0.5,0.25,0.55,0.44,0.28,0.44,0.78,0.28,0.5,0.44,0.5,0.78,0.44,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">secutive days 12 months later, and as-needed alemtuzumab </text>
   <text y="335.078" x="297.264,300.261,304.257,307.254,309.756,312.753,316.749,320.745,323.247,330.249,334.245,338.745,341.247,343.497,346.314,348.816,353.316,355.566,358.383,362.379,366.879,369.129,371.946,376.446,380.946,385.446,389.946,392.448,396.948,401.448,403.698,406.515,410.511,415.011,417.513,421.509,426.009,429.51,432.012,436.512,441.012,443.262,446.079,449.58,452.082,456.582,461.082,465.582,467.832,470.649,473.646,480.144,486.147,491.646,496.146,500.646,505.146,509.646,514.146,518.646,523.146,527.646,530.643,532.893" svgx:width="0.33,0.44,0.33,0.28,0.33,0.44,0.44,0.28,0.78,0.44,0.5,0.28,0.25,0.55,0.28,0.5,0.25,0.55,0.44,0.5,0.25,0.55,0.5,0.5,0.5,0.5,0.28,0.5,0.5,0.25,0.55,0.44,0.5,0.28,0.44,0.5,0.39,0.28,0.5,0.5,0.25,0.55,0.39,0.28,0.5,0.5,0.5,0.25,0.55,0.33,0.72,0.67,0.61,0.5,0.5,0.5,0.5,0.5,0.5,0.5,0.5,0.33,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">re-treatment in an ongoing extension study (NCT00930553). </text>
   <text y="346.076" x="297.264,300.261,306.759,312.762,316.263,318.513,325.011,329.007,332.004,336.0,338.25,342.75,346.746,349.743,352.245,356.745,360.741,365.241,367.491,371.487,374.988,377.238,381.234,385.734,390.234,391.989,398.487,403.986,406.236,410.736,414.732,418.728,423.228,426.225,429.222,431.724,436.224,440.724,442.974,447.474,451.47,453.972,460.47,464.466,468.462,472.962,475.212,478.713,481.215,485.211,488.208,490.71,492.96,496.956,501.456,505.956,508.206,511.707,514.209,518.709,523.209,525.459,529.959,532.956" svgx:width="0.33,0.72,0.67,0.39,0.25,0.72,0.44,0.33,0.44,0.25,0.5,0.44,0.33,0.28,0.5,0.44,0.5,0.25,0.44,0.39,0.25,0.44,0.5,0.5,0.25,0.72,0.61,0.25,0.5,0.44,0.44,0.5,0.33,0.33,0.28,0.5,0.5,0.25,0.5,0.44,0.28,0.72,0.44,0.44,0.5,0.25,0.39,0.28,0.44,0.33,0.28,0.25,0.44,0.5,0.5,0.25,0.39,0.28,0.5,0.5,0.25,0.5,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">IARs were defined as any AE occurring between start and stop of </text>
   <text y="357.074" x="297.264,301.26,305.76,310.26,312.51,313.752,316.254,320.754,323.751,328.251,331.752,334.254,338.754,343.254,345.504,346.746,351.246,354.243,356.493,357.735,364.233,366.735,369.237,373.737,376.239,380.739,382.989,384.231,388.731,393.231,395.481,396.723,401.223,405.723,410.223,413.22,416.721,418.971,420.213,424.209,427.206,429.708,433.704,436.701,438.951,440.193,442.695,447.195,451.191,453.441,454.683,458.679,463.179,467.679,469.929,471.171,475.671,478.668,480.918,482.16,484.663,489.163,492.16,496.66,500.161,502.663,507.163,511.663,513.913,516.163,517.405,520.402,526.9,532.903" svgx:width="0.44,0.5,0.5,0.25,0.55,0.28,0.5,0.33,0.5,0.39,0.28,0.5,0.5,0.25,0.55,0.5,0.33,0.25,0.55,0.72,0.28,0.28,0.5,0.28,0.5,0.25,0.55,0.5,0.5,0.25,0.55,0.5,0.5,0.5,0.33,0.39,0.25,0.55,0.44,0.33,0.28,0.44,0.33,0.25,0.55,0.28,0.5,0.44,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.5,0.33,0.25,0.55,0.28,0.5,0.33,0.5,0.39,0.28,0.5,0.5,0.25,0.25,0.55,0.33,0.72,0.67,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">any infusion or within 24 hours after the end of infusion. IAR </text>
   <text y="368.072" x="297.264,299.766,304.266,308.262,310.764,315.264,319.26,323.76,327.756,331.752,334.002,335.325,341.823,345.819,349.32,351.57,352.893,357.393,361.389,364.89,368.886,373.386,375.636,376.959,381.459,385.959,388.209,389.532,392.034,396.534,400.53,402.78,404.103,408.603,413.103,420.105,424.605,428.601,431.598,433.848,435.171,439.671,442.668,444.918,446.241,448.743,451.74,455.736,459.732,462.234,466.23,470.73,472.98,474.303,478.803,482.799,485.301,487.803,491.799,496.299,498.801,502.302,504.552,505.875,508.377,512.877,515.127,516.45,520.446,524.442,528.438,532.938" svgx:width="0.28,0.5,0.44,0.28,0.5,0.44,0.5,0.44,0.44,0.25,0.55,0.72,0.44,0.39,0.25,0.55,0.5,0.44,0.39,0.44,0.5,0.25,0.55,0.5,0.5,0.25,0.55,0.28,0.5,0.44,0.25,0.55,0.5,0.5,0.78,0.5,0.44,0.33,0.25,0.55,0.5,0.33,0.25,0.55,0.28,0.33,0.44,0.44,0.28,0.44,0.5,0.25,0.55,0.5,0.44,0.28,0.28,0.44,0.5,0.28,0.39,0.25,0.55,0.28,0.5,0.25,0.55,0.44,0.44,0.44,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">incidence was based on the number of treated patients in each </text>
   <text y="379.07" x="297.264,299.766,302.763,306.759,310.755,313.257,320.259,324.255,328.755,331.257,333.507,337.503,342.003,346.503,349.5,353.001,356.997" svgx:width="0.28,0.33,0.44,0.44,0.28,0.78,0.44,0.5,0.28,0.25,0.44,0.5,0.5,0.33,0.39,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">treatment course.</text>
   <text y="390.068" x="297.264,303.762,307.758,311.259,316.263,318.765,321.762,325.263,328.26" svgx:width="0.72,0.44,0.39,0.56,0.28,0.33,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Results: </text>
   <text y="390.068" x="330.879,335.379,339.546,344.046,346.665,351.165,355.161,357.663,360.165,364.161,368.661,371.163,374.664,377.274,383.772,387.768,390.765,394.761,397.371,399.873,402.87,406.866,410.862,413.364,417.36,421.86,424.47,430.968,433.47,435.972,440.472,443.091,447.087,449.589,453.585,460.587,463.089,467.589,471.585,476.085,483.087,487.083,491.583,494.193,496.695,501.195,503.805,506.307,510.807,514.803,517.422,521.418,525.918,528.915,532.911" svgx:width="0.5,0.5,0.5,0.25,0.5,0.44,0.28,0.28,0.44,0.5,0.28,0.39,0.25,0.72,0.44,0.33,0.44,0.25,0.28,0.33,0.44,0.44,0.28,0.44,0.5,0.25,0.72,0.28,0.28,0.5,0.25,0.44,0.28,0.44,0.78,0.28,0.5,0.44,0.5,0.78,0.44,0.5,0.25,0.28,0.5,0.25,0.28,0.5,0.44,0.25,0.44,0.5,0.33,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">811 patients were treated with alemtuzumab in the core </text>
   <text y="401.066" x="297.264,300.765,303.267,307.767,312.267,314.769,318.765,322.266,324.768,327.513,332.013,336.513,341.013,343.758,347.754,352.254,354.756,358.752,361.749,365.745,370.245,372.99,375.492,379.992,383.988,386.733,390.729,395.229,397.731,401.727,406.227,409.728,412.23,416.73,421.23,423.48,426.225,432.723,437.223,441.219,444.216,446.961,451.461,455.961,463.458,466.203,470.703,473.7,476.445,480.945,484.941,487.443,489.945,493.941,498.441,500.943,504.444,507.189,511.689,514.191,518.691,521.436,525.936,530.436,532.938" svgx:width="0.39,0.28,0.5,0.5,0.28,0.44,0.39,0.28,0.25,0.5,0.5,0.5,0.25,0.44,0.5,0.28,0.44,0.33,0.44,0.5,0.25,0.28,0.5,0.44,0.25,0.44,0.5,0.28,0.44,0.5,0.39,0.28,0.5,0.5,0.25,0.25,0.72,0.5,0.44,0.33,0.25,0.5,0.5,0.83,0.25,0.5,0.33,0.25,0.5,0.44,0.28,0.28,0.44,0.5,0.28,0.39,0.25,0.5,0.28,0.5,0.25,0.5,0.5,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">studies; 742 entered the extension. Over 80% of patients did not </text>
   <text y="412.064" x="297.264,300.261,304.257,308.253,312.249,314.751,319.251,323.247,325.497,327.657,330.159,333.156,337.152,341.148,343.65,350.652,354.648,359.148,361.65,363.9,366.06,368.562,373.062,375.312,377.139,382.737,386.733,390.729,393.726,395.976,398.136,402.636,404.886,407.136,409.296,417.297,421.293,424.29,428.79,432.786,437.286,439.536,441.696,446.196,450.192,454.188,457.185,461.181,465.177,468.678,472.674,476.175,478.425,480.585,483.087,487.587,489.837,491.997,494.995,501.492,507.495,510.996,513.246,515.406,518.404,521.401,525.901,532.903" svgx:width="0.33,0.44,0.44,0.44,0.28,0.5,0.44,0.25,0.55,0.28,0.33,0.44,0.44,0.28,0.78,0.44,0.5,0.28,0.25,0.55,0.28,0.5,0.25,0.55,0.72,0.44,0.44,0.33,0.25,0.55,0.5,0.25,0.25,0.55,0.89,0.44,0.33,0.5,0.44,0.5,0.25,0.55,0.5,0.44,0.44,0.33,0.44,0.44,0.39,0.44,0.39,0.25,0.55,0.28,0.5,0.25,0.55,0.33,0.72,0.67,0.39,0.25,0.55,0.33,0.33,0.5,0.78,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">receive treatment in Year 3. Marked decreases in IARs from </text>
   <text y="423.062" x="297.264,303.267,307.767,312.267,315.264,318.765,322.761,325.011,326.883,331.383,333.633,335.505,338.502,343.002,347.502,349.752,354.252,361.749,364.746,366.996,368.868,371.37,375.87,378.12,379.992,385.995,390.495,394.995,397.992,401.493,405.489,407.739,409.611,414.111,416.361,418.233,421.23,425.73,430.23,432.48,436.98,444.477,447.474,449.724,451.596,456.096,460.092,463.089,466.59,469.092,472.593,475.095,479.091,483.591,485.841,487.704,490.207,494.707,496.957,498.829,504.832,509.332,513.832,516.829,520.33,524.326,526.576,528.448,532.948" svgx:width="0.67,0.5,0.5,0.33,0.39,0.44,0.25,0.55,0.5,0.25,0.55,0.33,0.5,0.5,0.25,0.5,0.83,0.33,0.25,0.55,0.28,0.5,0.25,0.55,0.67,0.5,0.5,0.33,0.39,0.44,0.25,0.55,0.5,0.25,0.55,0.33,0.5,0.5,0.25,0.5,0.83,0.33,0.25,0.55,0.5,0.44,0.33,0.39,0.28,0.39,0.28,0.44,0.5,0.25,0.55,0.28,0.5,0.25,0.55,0.67,0.5,0.5,0.33,0.39,0.44,0.25,0.55,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">Course 1 (84.7%) to Course 2 (68.6%) persisted in Course 3 </text>
   <text y="434.06" x="297.264,300.261,304.761,309.261,311.511,316.011,323.508,326.505,328.755,331.005,332.634,335.631,342.129,348.132,350.382,352.02,355.017,358.014,362.01,366.51,371.01,375.006,379.506,383.502,388.002,390.252,391.881,398.379,402.375,405.876,408.126,409.755,414.255,416.757,421.257,425.757,429.753,433.254,435.756,438.006,439.635,446.133,448.635,451.137,455.637,457.887,459.525,462.027,466.527,469.029,471.531,474.033,478.029,480.531,482.781,484.41,488.406,490.908,494.904,501.906,504.408,508.908,512.904,517.404,524.406,528.402,532.902" svgx:width="0.33,0.5,0.5,0.25,0.5,0.83,0.33,0.25,0.25,0.55,0.33,0.72,0.67,0.25,0.55,0.33,0.33,0.44,0.5,0.5,0.44,0.5,0.44,0.5,0.25,0.55,0.72,0.44,0.39,0.25,0.55,0.5,0.28,0.5,0.5,0.44,0.39,0.28,0.25,0.55,0.72,0.28,0.28,0.5,0.25,0.55,0.28,0.5,0.28,0.28,0.28,0.44,0.28,0.25,0.55,0.44,0.28,0.44,0.78,0.28,0.5,0.44,0.5,0.78,0.44,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">(62.9%). IAR frequency was highest with initial alemtuzumab </text>
   <text y="445.058" x="297.264,301.26,305.76,310.26,314.76,318.261,322.761,325.758,329.754,332.004,332.949,336.945,341.445,345.945,348.195,349.14,353.64,357.636,362.136,366.132,369.129,373.125,375.627,378.129,382.629,384.879,385.824,390.324,394.32,398.316,401.313,405.309,409.305,412.806,416.802,421.302,423.552,424.497,430.995,433.497,435.999,440.499,442.749,443.694,447.69,451.686,455.682,460.182,462.432,463.377,465.879,470.379,473.376,477.876,481.377,483.879,488.379,492.879,495.129,496.074,500.574,504.57,508.486,510.736,512.986,513.93,516.927,523.425,529.428,532.929" svgx:width="0.44,0.5,0.5,0.5,0.39,0.5,0.33,0.44,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.5,0.44,0.5,0.44,0.33,0.44,0.28,0.28,0.5,0.25,0.55,0.5,0.44,0.44,0.33,0.44,0.44,0.39,0.44,0.5,0.25,0.55,0.72,0.28,0.28,0.5,0.25,0.55,0.44,0.44,0.44,0.5,0.25,0.55,0.28,0.5,0.33,0.5,0.39,0.28,0.5,0.5,0.25,0.55,0.5,0.44,0.5,0.25,0.25,0.55,0.33,0.72,0.67,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">exposure and generally decreased with each infusion day. IARs </text>
   <text y="456.056" x="297.264,303.762,307.758,310.755,314.751,317.001,318.324,322.824,325.821,329.817,334.317,338.817,345.819,348.321,352.821,356.817,361.317,363.819,366.321,370.821,373.071,374.394,381.396,383.898,386.4,390.9,393.15,394.473,396.975,401.475,403.725,405.048,412.05,416.55,421.05,425.046,428.043,432.039,434.541,438.537,441.039,443.289,444.612,449.112,453.612,458.112,462.108,464.358,465.681,468.183,472.179,476.679,478.929,480.252,482.754,487.254,489.504,490.827,494.328,496.831,501.331,505.831,510.331,512.581,513.904,520.401,522.904,525.406,529.906" svgx:width="0.72,0.44,0.33,0.44,0.25,0.55,0.5,0.33,0.44,0.5,0.5,0.78,0.28,0.5,0.44,0.5,0.28,0.28,0.5,0.25,0.55,0.78,0.28,0.28,0.5,0.25,0.55,0.28,0.5,0.25,0.55,0.78,0.5,0.5,0.44,0.33,0.44,0.28,0.44,0.28,0.25,0.55,0.5,0.5,0.5,0.44,0.25,0.55,0.28,0.44,0.5,0.25,0.55,0.28,0.5,0.25,0.55,0.39,0.28,0.5,0.5,0.5,0.25,0.55,0.72,0.28,0.28,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">were predominantly mild to moderate; none led to study with-</text>
   <text y="467.054" x="297.264,301.764,304.761,308.757,315.255,319.251,321.753,324.57,329.07,332.067,334.875,339.375,343.371,347.367,349.869,354.369,356.619,359.436,364.44,368.436,371.433,373.935,378.435,382.935,386.436,389.253,392.25,398.748,404.751,408.252,411.06,417.558,421.554,424.551,428.547,431.364,434.361,438.357,441.354,445.35,448.167,451.164,455.664,457.914,462.414,469.911,472.719,477.219,480.216,483.033,487.533,491.529,494.031,496.533,500.529,505.029,507.531,511.032,514.029,516.279,518.925,524.424,528.924,532.92" svgx:width="0.5,0.33,0.44,0.72,0.44,0.28,0.25,0.5,0.33,0.25,0.5,0.44,0.44,0.28,0.5,0.25,0.25,0.56,0.44,0.33,0.28,0.5,0.5,0.39,0.25,0.33,0.72,0.67,0.39,0.25,0.72,0.44,0.33,0.44,0.25,0.33,0.44,0.33,0.44,0.25,0.33,0.5,0.25,0.5,0.83,0.25,0.5,0.33,0.25,0.5,0.44,0.28,0.28,0.44,0.5,0.28,0.39,0.33,0.25,0.25,0.61,0.5,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">drawal or death. Serious IARs were rare (3.1% of patients). The </text>
   <text y="478.052" x="297.264,304.266,308.766,312.267,314.769,317.019,319.224,323.22,327.72,334.722,341.724,346.224,350.724,352.974,355.179,358.176,364.674,370.677,372.927,375.132,377.634,382.134,386.634,390.63,394.131,396.381,398.586,405.084,409.08,412.077,416.073,418.323,420.528,424.029,428.529,431.031,435.531,437.781,439.986,444.486,446.988,450.489,454.989,457.986,462.486,466.482,469.479,472.98,475.23,477.435,480.432,484.932,487.929,491.925,496.425,500.925,507.927,510.429,514.929,518.925,523.425,525.927,528.429,532.929" svgx:width="0.78,0.5,0.39,0.28,0.25,0.55,0.44,0.5,0.78,0.78,0.5,0.5,0.25,0.55,0.33,0.72,0.67,0.25,0.55,0.28,0.5,0.5,0.44,0.39,0.25,0.55,0.72,0.44,0.33,0.44,0.25,0.55,0.39,0.5,0.28,0.5,0.25,0.55,0.5,0.28,0.39,0.5,0.33,0.5,0.44,0.33,0.39,0.25,0.55,0.33,0.5,0.33,0.44,0.5,0.5,0.78,0.28,0.5,0.44,0.5,0.28,0.28,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">most common IAR types were skin disorders (predominantly </text>
   <text y="489.05" x="297.264,300.261,304.257,307.758,312.258,315.255,317.505,319.755,321.222,325.722,329.718,333.714,338.214,342.21,346.206,350.706,354.702,356.952,359.202,360.669,365.169,369.669,372.666,376.662,381.162,383.664,387.66,389.91,392.16,393.627,397.623,402.123,406.623,408.873,410.34,414.84,418.836,423.336,426.837,430.833,434.829,437.079,439.329,440.796,447.294,451.794,455.79,458.04,459.507,463.503,467.499,471.0,474.996,477.246,478.713,483.213,486.21,488.46,489.927,493.923,498.423,502.419,506.919,511.419,515.919,518.421,522.417,526.917,529.419,532.92" svgx:width="0.33,0.44,0.39,0.5,0.33,0.25,0.25,0.55,0.5,0.44,0.44,0.5,0.44,0.44,0.5,0.44,0.25,0.25,0.55,0.5,0.5,0.33,0.44,0.5,0.28,0.44,0.25,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.5,0.44,0.5,0.39,0.44,0.44,0.25,0.25,0.55,0.72,0.5,0.44,0.25,0.55,0.44,0.44,0.39,0.44,0.25,0.55,0.5,0.33,0.25,0.55,0.44,0.5,0.44,0.5,0.5,0.5,0.28,0.44,0.5,0.28,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">rash), headache, pyrexia, and nausea. One case of anaphylaxis </text>
   <text y="500.048" x="297.264,301.764,305.76,309.756,314.256,317.253,320.25,324.246,328.746,330.996,332.148,336.648,341.148,344.145,346.647,351.147,355.647,357.897,359.049,365.052,369.552,374.052,377.049,380.55,384.546,386.796,387.948,392.448,394.698,395.85,399.846,404.346,408.846,411.096,412.248,415.245,419.241,422.742,427.242,429.744,434.244,438.24,442.74,444.99,446.142,452.64,455.142,457.644,462.144,464.394,465.546,468.048,471.045,475.041,479.037,481.539,488.542,492.538,497.038,499.54,502.042,504.292,505.444,509.44,511.942,515.938,522.94,525.442,529.942" svgx:width="0.5,0.44,0.44,0.5,0.33,0.33,0.44,0.5,0.25,0.55,0.5,0.5,0.33,0.28,0.5,0.5,0.25,0.55,0.67,0.5,0.5,0.33,0.39,0.44,0.25,0.55,0.5,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.33,0.44,0.39,0.5,0.28,0.5,0.44,0.5,0.25,0.55,0.72,0.28,0.28,0.5,0.25,0.55,0.28,0.33,0.44,0.44,0.28,0.78,0.44,0.5,0.28,0.28,0.25,0.55,0.44,0.28,0.44,0.78,0.28,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">occurred during Course 3 and resolved with treatment; alemtu-</text>
   <text y="511.046" x="297.264,301.26,305.76,312.762,316.758,321.258,323.508,324.777,327.279,330.276,334.272,338.268,340.77,347.772,351.768,356.268,358.77,361.02,362.289,368.787,372.783,376.284,378.534,379.803,384.303,386.805,390.306,394.302,398.802,403.302,405.804,408.306,412.806,417.306,421.302,425.802,428.052,430.302,431.571,437.07,439.905,442.902,446.898,450.895,453.397,455.899,460.399,464.395,466.645,467.914,470.911,477.409,483.412,485.662,486.931,493.933,497.929,502.429,506.425,510.925,514.921,521.923,525.919,530.419,532.921" svgx:width="0.44,0.5,0.78,0.44,0.5,0.25,0.55,0.28,0.33,0.44,0.44,0.28,0.78,0.44,0.5,0.28,0.25,0.55,0.72,0.44,0.39,0.25,0.55,0.5,0.28,0.39,0.44,0.5,0.5,0.28,0.28,0.5,0.5,0.44,0.5,0.25,0.25,0.55,0.61,0.33,0.33,0.44,0.44,0.28,0.28,0.5,0.44,0.25,0.55,0.33,0.72,0.67,0.25,0.55,0.78,0.44,0.5,0.44,0.5,0.44,0.78,0.44,0.5,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">zumab treatment was discontinued. Effective IAR management </text>
   <text y="522.044" x="297.264,299.766,304.266,308.262,310.764,315.264,319.764,323.76,328.26,330.366,334.866,337.863,341.859,345.855,348.357,350.859,354.855,358.851,362.352,364.449,368.949,372.945,375.942,380.442,383.439,387.435,389.532,392.034,396.534,399.531,404.031,407.532,410.034,414.534,419.034,421.14,424.137,428.637,432.633,435.135,437.637,441.633,446.133,448.635,450.732,454.728,459.228,463.728,467.724,471.72,474.222,476.724,481.224,485.724,487.821,491.817,496.317,500.817,502.923,507.423,510.42,514.416,521.418,525.414,529.914" svgx:width="0.28,0.5,0.44,0.28,0.5,0.5,0.44,0.5,0.25,0.5,0.33,0.44,0.44,0.28,0.28,0.44,0.44,0.39,0.25,0.5,0.44,0.33,0.5,0.33,0.44,0.25,0.28,0.5,0.33,0.5,0.39,0.28,0.5,0.5,0.25,0.33,0.5,0.44,0.28,0.28,0.44,0.5,0.28,0.25,0.44,0.5,0.5,0.44,0.44,0.28,0.28,0.5,0.5,0.25,0.44,0.5,0.5,0.25,0.5,0.33,0.44,0.78,0.44,0.5,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">included practices before infusion (patient education and premed-</text>
   <text y="533.042" x="297.264,299.766,303.762,307.758,310.26,312.762,317.262,321.762,324.012,329.304,332.301,339.303,343.299,345.801,350.301,354.801,357.303,361.803,364.8,368.796,373.296,377.796,380.298,383.799,388.299,390.801,395.301,399.801,403.797,406.794,409.791,412.041,414.291,419.583,424.083,428.583,431.58,434.082,438.582,443.082,445.332,450.624,453.126,457.626,460.623,465.123,468.624,471.126,475.626,480.126,482.376,487.668,490.665,497.668,502.168,506.668,509.17,511.672,516.172,519.169,521.671,526.171,530.671,532.921" svgx:width="0.28,0.44,0.44,0.28,0.28,0.5,0.5,0.25,0.55,0.33,0.78,0.44,0.28,0.5,0.5,0.28,0.5,0.33,0.44,0.5,0.5,0.28,0.39,0.5,0.28,0.5,0.5,0.44,0.33,0.33,0.25,0.25,0.55,0.5,0.5,0.33,0.28,0.5,0.5,0.25,0.55,0.28,0.5,0.33,0.5,0.39,0.28,0.5,0.5,0.25,0.55,0.33,0.78,0.5,0.5,0.28,0.28,0.5,0.33,0.28,0.5,0.5,0.25,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">ication [methylprednisolone]), during infusion (monitoring, </text>
   <text y="544.04" x="297.264,300.765,305.265,312.267,316.767,319.269,323.769,330.771,334.767,337.269,339.771,343.767,346.017,349.248,351.75,354.747,358.743,362.739,365.241,372.243,376.239,380.739,383.241,385.491,387.741,390.972,394.968,399.468,403.968,406.218,409.449,411.951,416.451,419.448,423.948,427.449,429.951,434.451,438.951,441.201,444.432,446.934,451.434,453.936,457.932,460.929,463.926,468.426,472.926,475.428,477.931,482.431,486.931,489.433,492.43,496.426,498.928,502.924,505.174,508.405,512.401,516.901,519.403,523.903,527.404,529.906" svgx:width="0.39,0.5,0.78,0.5,0.28,0.5,0.78,0.44,0.28,0.28,0.44,0.25,0.55,0.28,0.33,0.44,0.44,0.28,0.78,0.44,0.5,0.28,0.25,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.28,0.5,0.33,0.5,0.39,0.28,0.5,0.5,0.25,0.55,0.28,0.5,0.28,0.44,0.33,0.33,0.5,0.5,0.28,0.28,0.5,0.5,0.28,0.33,0.44,0.28,0.44,0.25,0.55,0.44,0.5,0.28,0.5,0.39,0.28,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">symptomatic treatment, and infusion interruption/rate adjust-</text>
   <text y="555.038" x="297.264,304.266,308.262,312.762,315.264,318.261,320.511,322.761,323.499,327.495,331.995,336.495,338.745,339.492,343.488,346.485,348.987,352.983,355.98,358.23,358.968,361.47,365.97,368.967,373.467,376.968,379.47,383.97,388.47,390.72,391.458,394.455,398.451,402.951,407.451,409.953,412.455,416.955,421.455,425.451,429.951,432.201,432.939,439.941,444.441,448.941,451.444,453.946,458.446,461.443,463.945,468.445,472.945,475.195,475.942,478.939,483.439,486.436,488.686,489.424,493.924,496.174,496.921,501.421,505.921,510.421,513.418,516.919,519.169,519.907,523.903,528.403,532.903" svgx:width="0.78,0.44,0.5,0.28,0.33,0.25,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.44,0.33,0.28,0.44,0.33,0.25,0.55,0.28,0.5,0.33,0.5,0.39,0.28,0.5,0.5,0.25,0.55,0.33,0.44,0.5,0.5,0.28,0.28,0.5,0.5,0.44,0.5,0.25,0.55,0.78,0.5,0.5,0.28,0.28,0.5,0.33,0.28,0.5,0.5,0.25,0.55,0.33,0.5,0.33,0.25,0.55,0.5,0.25,0.55,0.5,0.5,0.5,0.33,0.39,0.25,0.55,0.44,0.5,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">ment), and after infusion (continued monitoring for 2 hours and </text>
   <text y="566.036" x="297.264,300.765,305.265,312.267,316.767,319.269,323.769,330.771,334.767,337.269,339.771,343.767,346.602,349.104,352.101,356.097,360.093,362.595,369.597,373.593,378.093,380.595,383.43,386.427,390.423,394.923,397.425,399.927,404.427,406.929,410.43,412.932,416.928,423.931,426.433,430.933,434.929,438.43,440.68,443.515,447.511,452.011,454.513,457.015,461.515,466.015,469.012,473.008,475.51,478.012,482.008,485.509,487.759,490.594,494.59,499.09,503.59,506.092,510.592,513.589,516.424,520.42,524.92,527.422,529.924" svgx:width="0.39,0.5,0.78,0.5,0.28,0.5,0.78,0.44,0.28,0.28,0.44,0.25,0.28,0.33,0.44,0.44,0.28,0.78,0.44,0.5,0.28,0.25,0.33,0.44,0.5,0.28,0.28,0.5,0.28,0.39,0.28,0.44,0.78,0.28,0.5,0.44,0.39,0.25,0.25,0.44,0.5,0.28,0.28,0.5,0.5,0.33,0.44,0.28,0.28,0.44,0.39,0.25,0.25,0.44,0.5,0.5,0.28,0.5,0.33,0.25,0.44,0.5,0.28,0.28,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">symptomatic treatment [antihistamines, antipyretics, and/or anti-</text>
   <text y="577.034" x="297.264,301.26,308.262,312.258,314.76,317.262,321.258,324.759,327.756,330.753,333.003,335.253,340.824,345.828,349.824,356.322,358.572,364.143,368.643,372.639,375.141,377.643,381.639,386.139,388.641,392.142,394.392,399.963,402.96,406.956,411.456,415.956,418.458,421.455,425.451,429.951,432.201,437.772,440.275,444.775,447.772,452.272,455.773,458.275,462.775,467.275,469.525,475.096,477.598,482.098,484.6,488.596,491.593,494.59,499.09,503.59,506.092,508.594,513.094,517.594,519.844,525.415,529.915,532.912" svgx:width="0.44,0.78,0.44,0.28,0.28,0.44,0.39,0.33,0.33,0.25,0.25,0.55,0.56,0.44,0.72,0.25,0.55,0.5,0.44,0.28,0.28,0.44,0.5,0.28,0.39,0.25,0.55,0.33,0.44,0.5,0.5,0.28,0.33,0.44,0.5,0.25,0.55,0.28,0.5,0.33,0.5,0.39,0.28,0.5,0.5,0.25,0.55,0.28,0.5,0.28,0.44,0.33,0.33,0.5,0.5,0.28,0.28,0.5,0.5,0.25,0.55,0.5,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">emetics]). Few patients required infusion interruption or </text>
   <text y="588.032" x="297.264,301.26,305.76,308.262,312.762,316.263,318.765,325.767,329.763,334.263,336.765" svgx:width="0.44,0.5,0.28,0.5,0.39,0.28,0.78,0.44,0.5,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">adjustment.</text>
   <text y="599.03" x="297.264,303.762,308.262,313.266,317.262,319.764,324.768,328.269,330.771,335.271,340.275,343.776,346.773" svgx:width="0.72,0.5,0.56,0.44,0.28,0.56,0.39,0.28,0.5,0.56,0.39,0.33,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">Conclusions: </text>
   <text y="599.03" x="350.301,353.298,359.796,365.799,369.3,371.55,372.828,379.326,383.322,386.319,390.315,392.565,393.843,397.839,402.339,409.341,416.343,420.843,425.343,427.593,428.871,435.369,437.871,440.373,444.873,447.123,448.401,452.397,454.899,458.895,465.897,468.399,472.899,476.895,481.395,488.397,492.393,496.893,499.143,500.421,504.921,509.421,511.923,514.173,515.451,521.949,525.945,528.942,532.938" svgx:width="0.33,0.72,0.67,0.39,0.25,0.55,0.72,0.44,0.33,0.44,0.25,0.55,0.44,0.5,0.78,0.78,0.5,0.5,0.25,0.55,0.72,0.28,0.28,0.5,0.25,0.55,0.44,0.28,0.44,0.78,0.28,0.5,0.44,0.5,0.78,0.44,0.5,0.25,0.55,0.5,0.5,0.28,0.25,0.55,0.72,0.44,0.33,0.44,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">IARs were common with alemtuzumab but were </text>
   <text y="610.028" x="297.264,301.764,304.761,308.757,313.257,317.757,324.759,327.261,331.761,335.757,340.257,342.759,345.261,349.761,352.011,353.649,360.651,363.153,365.655,370.155,372.405,374.043,378.543,381.54,383.79,385.428,392.43,396.93,401.43,405.426,408.423,412.419,414.921,418.917,421.167,422.805,426.801,431.301,435.801,438.051,439.689,444.189,448.185,452.181,455.178,459.174,463.17,466.671,470.667,475.167,477.417,479.055,485.553,488.055,490.557,495.057,497.307,498.945,501.448,504.445,508.441,512.437,514.939,521.941,525.937,530.437,532.939" svgx:width="0.5,0.33,0.44,0.5,0.5,0.78,0.28,0.5,0.44,0.5,0.28,0.28,0.5,0.25,0.55,0.78,0.28,0.28,0.5,0.25,0.55,0.5,0.33,0.25,0.55,0.78,0.5,0.5,0.44,0.33,0.44,0.28,0.44,0.25,0.55,0.44,0.5,0.5,0.25,0.55,0.5,0.44,0.44,0.33,0.44,0.44,0.39,0.44,0.5,0.25,0.55,0.72,0.28,0.28,0.5,0.25,0.55,0.28,0.33,0.44,0.44,0.28,0.78,0.44,0.5,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">predominantly mild or moderate and decreased with treatment </text>
   <text y="621.026" x="297.264,301.26,305.76,310.26,313.257,316.758,320.754,324.255,326.505,328.755,329.439,332.436,338.934,344.937,348.438,350.688,351.372,357.87,361.866,364.863,368.859,371.109,371.784,378.786,381.288,385.788,388.29,395.292,397.794,401.79,405.786,410.286,412.536,413.22,417.72,420.717,422.967,423.651,430.653,434.649,439.149,443.145,447.645,451.641,456.141,458.391,459.075,463.575,468.075,471.072,473.574,478.074,482.574,484.824,485.508,489.504,492.006,494.508,499.008,501.51,505.506,509.502,512.004,514.254,514.938,517.44,520.437,522.939,526.935,529.437,532.938" svgx:width="0.44,0.5,0.5,0.33,0.39,0.44,0.39,0.25,0.25,0.55,0.33,0.72,0.67,0.39,0.25,0.55,0.72,0.44,0.33,0.44,0.25,0.55,0.78,0.28,0.5,0.28,0.78,0.28,0.44,0.44,0.5,0.25,0.55,0.5,0.33,0.25,0.55,0.78,0.44,0.5,0.44,0.5,0.44,0.5,0.25,0.55,0.5,0.5,0.33,0.28,0.5,0.5,0.25,0.55,0.44,0.28,0.28,0.5,0.28,0.44,0.44,0.28,0.25,0.55,0.28,0.33,0.28,0.44,0.28,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">courses. IARs were minimized or managed during clinical trials </text>
   <text y="632.024" x="297.264,303.762,306.264,308.766,313.266,315.516,316.506,320.502,325.002,329.502,332.499,336.999,341.499,344.496,346.998,350.994,353.496,357.492,359.742,360.732,365.232,369.228,371.73,374.232,378.228,382.728,385.23,387.48,388.47,392.466,396.966,401.466,405.462,409.458,411.96,414.462,418.962,423.462,425.712,427.962,428.952,435.954,439.95,444.45,446.952,450.948,454.944,457.446,459.948,464.448,468.948,471.198,473.448,474.438,481.44,485.94,490.44,492.942,495.444,499.944,502.941,505.444,509.944,514.443,516.693,518.943,519.933,523.929,528.429,532.929" svgx:width="0.72,0.28,0.28,0.5,0.25,0.55,0.44,0.5,0.5,0.33,0.5,0.5,0.33,0.28,0.44,0.28,0.44,0.25,0.55,0.5,0.44,0.28,0.28,0.44,0.5,0.28,0.25,0.55,0.44,0.5,0.5,0.44,0.44,0.28,0.28,0.5,0.5,0.25,0.25,0.55,0.78,0.44,0.5,0.28,0.44,0.44,0.28,0.28,0.5,0.5,0.25,0.25,0.55,0.78,0.5,0.5,0.28,0.28,0.5,0.33,0.28,0.5,0.5,0.25,0.25,0.55,0.44,0.5,0.5,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">with appropriate patient education, medication, monitoring, and </text>
   <text y="643.022" x="297.264,299.766,304.266,307.263,311.763,315.264,317.766,322.266,326.766,329.016,333.012,337.512,340.014,344.514,348.015,350.517,357.519,361.515,366.015,368.517" svgx:width="0.28,0.5,0.33,0.5,0.39,0.28,0.5,0.5,0.25,0.44,0.5,0.28,0.5,0.39,0.28,0.78,0.44,0.5,0.28,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">infusion adjustment.</text>
   <text y="670.022" x="297.264,302.763,307.263,311.763" svgx:width="0.61,0.5,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">P881</text>
   <text y="681.02" x="297.264,301.764,308.262,314.76,317.01,321.51,326.514,329.511,332.013,337.017,341.517,346.521,351.021,353.271,355.773,360.777,365.781,369.777,374.277,376.527,381.027,386.031,391.035,393.285,397.785,402.789,407.793,411.789,415.29,417.792,422.292,427.296,429.546,437.043,441.543,444.045,448.041,452.037,457.041,459.543,463.539,465.789,469.785,474.285,479.289,483.285,487.281,490.782,494.283,496.785,501.285,506.289" svgx:width="0.5,0.72,0.72,0.25,0.5,0.56,0.33,0.28,0.56,0.5,0.56,0.5,0.25,0.28,0.56,0.56,0.44,0.5,0.25,0.5,0.56,0.56,0.25,0.5,0.56,0.56,0.44,0.39,0.28,0.5,0.56,0.25,0.83,0.5,0.28,0.44,0.44,0.56,0.28,0.44,0.25,0.44,0.5,0.56,0.44,0.44,0.39,0.39,0.28,0.5,0.56,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">JCV antibody index and adhesion molecule expression </text>
   <text y="692.018" x="297.264,299.766,303.762,308.262,312.258,314.76,318.261,320.511,323.013,328.017,330.267,335.271,339.771,342.768,347.268,349.77,352.272,356.268,361.272,368.769,373.269,378.273,381.27,384.267,388.263,392.259,396.759,399.756,403.752,408.756,411.006,418.503,423.507,426.009,429.006,431.508,436.512,439.014,443.01,445.26,448.761,452.757,455.259,459.255,463.251,467.751,471.253,473.755,477.256,479.506,484.51,489.01,492.007,494.509,498.505,503.509,506.506,510.007" svgx:width="0.28,0.44,0.5,0.44,0.28,0.39,0.25,0.28,0.56,0.25,0.56,0.5,0.33,0.5,0.28,0.28,0.44,0.56,0.83,0.5,0.56,0.33,0.33,0.44,0.44,0.5,0.33,0.44,0.56,0.25,0.83,0.56,0.28,0.33,0.28,0.56,0.28,0.44,0.25,0.39,0.44,0.28,0.44,0.44,0.5,0.39,0.28,0.39,0.25,0.56,0.5,0.33,0.28,0.44,0.56,0.33,0.39,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">levels in natalizumab-treated multiple sclerosis patients </text>
   <text y="703.016" x="297.264,300.261,302.511,307.011,309.261,313.257,317.253,321.753,325.254,328.755,331.752,335.253,339.249,343.245,346.242,348.744,353.244,358.248,362.748,365.25,367.5,371.001,373.998,379.002,384.006" svgx:width="0.33,0.25,0.5,0.25,0.44,0.44,0.5,0.39,0.39,0.33,0.39,0.44,0.44,0.33,0.28,0.5,0.56,0.5,0.28,0.25,0.39,0.33,0.56,0.56,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-BoldMT;font-size:9.0px;stroke:none;">- a cross-sectional study</text>
   <text y="714.014" x="297.264,302.268,304.518,313.014,315.516,320.016,323.013,325.515,329.511" svgx:width="0.56,0.25,0.94,0.28,0.5,0.33,0.28,0.44,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">P Wipfler</text>
   <text y="711.592" x="332.503" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="714.112" x="335.428,337.678,339.928,346.426,348.676,355.174,359.17,362.167,365.164,369.16" svgx:width="0.25,0.25,0.72,0.25,0.72,0.44,0.33,0.33,0.44,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, A Harrer</text>
   <text y="711.592" x="372.157" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="714.112" x="375.082,377.332,379.582,386.08,388.33,393.334,395.836,398.338" svgx:width="0.25,0.25,0.72,0.25,0.56,0.28,0.28,0.44" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, G Pilz</text>
   <text y="711.592" x="402.333" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="714.112" x="405.258,407.508,409.758,416.256,418.506,425.004,429.504,434.004,438.0,440.997,447.999,451.995,456.495" svgx:width="0.25,0.25,0.72,0.25,0.72,0.5,0.5,0.44,0.33,0.78,0.44,0.5,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, K Oppermann</text>
   <text y="711.592" x="460.995" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="714.112" x="463.92,466.17,468.42,471.921,474.171,479.175,483.171,485.673,488.175,492.675,496.671" svgx:width="0.25,0.25,0.39,0.25,0.56,0.44,0.28,0.28,0.5,0.44,0.33" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, J Sellner</text>
   <text y="711.592" x="499.667" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="714.112" x="502.592,504.842,507.092,512.591" svgx:width="0.25,0.25,0.61,0.25" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, E </text>
   <text y="725.11" x="297.257,302.756,305.753,308.255,312.755,317.255" svgx:width="0.61,0.33,0.28,0.5,0.5,0.44" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">Trinka</text>
   <text y="722.592" x="321.254" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="725.112" x="324.179,326.429,328.679,332.18,334.43,340.928,343.925,347.921,352.421" svgx:width="0.25,0.25,0.39,0.25,0.72,0.33,0.44,0.5,0.39" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:9.0px;stroke:none;">, J Kraus</text>
   <text y="722.592" x="355.921" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPSMT;font-size:5.85px;stroke:none;">1</text>
   <text y="733.59" x="297.257" svgx:width="0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:5.85px;stroke:none;">1</text>
   <text y="736.112" x="300.185,305.684,310.184,313.685,318.185,322.181,326.177,328.679,332.18,336.68,340.181,342.431,349.928,353.924,358.424,360.926,364.922,369.422,371.924,374.174,380.672,385.172,387.674,391.67,395.666,399.167,402.668,405.17,407.672,411.668,413.918,416.168,422.171,426.167,430.667,434.168,438.668,441.17,445.67,450.17,454.166,456.416,458.666,463.166,467.666,470.168,473.669,478.169,482.669,486.17,490.67,492.92,495.17,500.669,505.169,508.67,511.172,514.673,517.175" svgx:width="0.61,0.5,0.39,0.5,0.44,0.44,0.28,0.39,0.5,0.39,0.25,0.83,0.44,0.5,0.28,0.44,0.5,0.28,0.25,0.72,0.5,0.28,0.44,0.44,0.39,0.39,0.28,0.28,0.44,0.25,0.25,0.67,0.44,0.5,0.39,0.5,0.28,0.5,0.5,0.44,0.25,0.25,0.5,0.5,0.28,0.39,0.5,0.5,0.39,0.5,0.25,0.25,0.61,0.5,0.39,0.28,0.39,0.28,0.5" style="fill:rgb(0,0,0);font-family:TimesNewRomanPS-ItalicMT;font-size:9.0px;stroke:none;">Paracelsus Medical University, Neurology, Salzburg, Austria</text>
  </g>
 </g>
</svg>
